

John J V McMurray

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5419095/john-j-v-mcmurray-publications-by-year.pdf>

Version: 2023-06-07

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

1,162
papers

153,471
citations

162
h-index

371
g-index

1,315
ext. papers

186,569
ext. citations

11.4
avg, IF

8.33
L-index

#	Paper	IF	Citations
1162	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC.. <i>European Journal of Heart Failure</i> , 2022 , 24, 4-131	3.1	50
1161	Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF.. <i>JACC: Heart Failure</i> , 2022 , 10, 104-118	2	0
1160	Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions.. <i>Kidney International Reports</i> , 2022 , 7, 699-707	1.1	1
1159	Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 504-510	3.8	0
1158	Drug therapy for HFrEF: What is the "right" dose?. <i>European Journal of Heart Failure</i> , 2022 ,	3.1	2
1157	Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction.. <i>JACC: Heart Failure</i> , 2022 , 10, 52-64	2	1
1156	Quetelet (Body Mass) Index and Effects of Dapagliflozin in CKD.. <i>Diabetes, Obesity and Metabolism</i> , 2022 ,	1.7	1
1155	The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists.. <i>Kidney International Reports</i> , 2022 , 7, 436-443	1.1	2
1154	Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.. <i>JACC: Heart Failure</i> , 2022 , 10, 184-197	2	4
1153	Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial.. <i>JACC: Heart Failure</i> , 2022 , 10, 306-318	2	1
1152	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.. <i>JACC: Heart Failure</i> , 2022 , 10, 336-346	2	0
1151	Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes.. <i>Journal of the American Heart Association</i> , 2022 , e021327	1.4	1
1150	Clinical cardiovascular phenotypes and the pattern of future events in patients with type 2 diabetes.. <i>Clinical Research in Cardiology</i> , 2022 , 1	1.2	
1149	Clinical characteristics and survival in patients with heart failure experiencing in hospital cardiac arrest.. <i>Scientific Reports</i> , 2022 , 12, 5685	1.5	0
1148	Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.. <i>Diabetologia</i> , 2022 , 1	2.4	1
1147	Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multistate model.. <i>American Heart Journal</i> , 2022 , 251, 13-13	1.3	0
1146	Apparent Treatment-Resistant Hypertension Across the Spectrum of Heart Failure Phenotypes in the Swedish HF Registry. <i>JACC: Heart Failure</i> , 2022 , 10, 380-392	2	0

1145	Adherence to prescribed medications in patients with heart failure: insights from liquid chromatography-tandem mass spectrometry-based urine analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 296-301	1.2	7
1144	Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.. <i>European Journal of Heart Failure</i> , 2021 ,	3.1	6
1143	Diabetes and prediabetes in patients with heart failure and preserved ejection fraction.. <i>European Journal of Heart Failure</i> , 2021 ,	3.1	3
1142	Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: A nationwide study in Denmark from 2003-2017.. <i>European Journal of Heart Failure</i> , 2021 ,	3.1	3
1141	Re-emergence of heart failure with a normal ejection fraction?. <i>European Heart Journal</i> , 2021 ,	3.5	2
1140	Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2021 ,	18	15
1139	Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2021 ,	18	14
1138	Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients with Heart Failure with Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. <i>Circulation</i> , 2021 ,	4.8	1
1137	Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2021 , CIRCHEARTFAILURE121008597	1.7	0
1136	Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. <i>Circulation</i> , 2021 ,	4.8	5
1135	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. <i>Lancet Diabetes and Endocrinology</i> , 2021 ,	4.9	3
1134	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. <i>European Journal of Heart Failure</i> , 2021 ,	3.1	5
1133	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Journal of the American Heart Association</i> , 2021 , 10, e021494	1.4	0
1132	Angiotensin Receptor-Nepriylsin Inhibition in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2021 , 385, 1845-1855	18	21
1131	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. <i>Circulation: Heart Failure</i> , 2021 , CIRCHEARTFAILURE121008837	1.7	2
1130	The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Analysis of the SONAR Randomized Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 ,	1.8	1
1129	Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. <i>Diabetes Care</i> , 2021 , 44, 586-594	3.9	24
1128	Growth differentiation factor 15 predicts poor prognosis in patients with heart failure and reduced ejection fraction and anemia: results from RED-HF. <i>Clinical Research in Cardiology</i> , 2021 , 111, 440	1.2	2

1127	Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 ,	4	9
1126	Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 743-754	4.9	9
1125	Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 755-766	4.9	10
1124	Non-fatal cardiovascular events preceding sudden cardiac death in patients with an acute myocardial infarction complicated by heart failure: insights from the high-risk myocardial infarction database. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 127-131	0.7	1
1123	Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). <i>Circulation</i> , 2021 , 143, 516-525	4.8	85
1122	Ultrasound imaging of congestion in heart failure: examinations beyond the heart. <i>European Journal of Heart Failure</i> , 2021 , 23, 703-712	3.1	21
1121	Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	1.2	3
1120	Effect of dapagliflozin on anaemia in DAPA-HF. <i>European Journal of Heart Failure</i> , 2021 , 23, 617-628	3.1	14
1119	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis. <i>Circulation: Heart Failure</i> , 2021 , 14, e008052	1.7	4
1118	Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1147-1155	3.1	4
1117	Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. <i>European Heart Journal</i> , 2021 , 42, 1216-1227	3.5	25
1116	How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine. <i>Circulation</i> , 2021 , 143, 875-877	4.8	57
1115	Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 601-613	3.1	14
1114	Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysis. <i>European Journal of Heart Failure</i> , 2021 , 23, 1346-1356	3.1	2
1113	Prospective ARNI vs. ACE inhibitor trial to Determine Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. <i>European Journal of Heart Failure</i> , 2021 , 23, 1040-1048	3.1	29
1112	Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1717-1727	3.8	8
1111	Incidence and Outcomes of Pneumonia in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1961-1973	3.8	7
1110	The struggle towards a Universal Definition of Heart Failure-how to proceed?. <i>European Heart Journal</i> , 2021 , 42, 2331-2343	3.5	19

1109	Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2021 , 14, e007901	1.7	2
1108	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. <i>JACC: Heart Failure</i> , 2021 , 9, 254-264	2	23
1107	MO559ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36,	1.2	1
1106	The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF). <i>European Journal of Heart Failure</i> , 2021 , 23, 1052-1056	3.1	4
1105	Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study. <i>International Journal of Cardiology</i> , 2021 , 330, 91-97	0.8	4
1104	Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2021 , 23, 882-894	3.1	26
1103	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. <i>Circulation</i> , 2021 , 143, 1962-1972	4.8	13
1102	Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2021 , 9, 386-397	2	2
1101	Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2021 , 9, 374-382	2	6
1100	Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1308-1320	1.2	1
1099	Urinary peptides in heart failure: a link to molecular pathophysiology. <i>European Journal of Heart Failure</i> , 2021 , 23, 1875-1887	3.1	14
1098	Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021 , 6, 499-507	4	35
1097	Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial. <i>Circulation: Heart Failure</i> , 2021 , 14, e008075	1.7	2
1096	Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. <i>Diabetes Care</i> , 2021 , 44, 1894-1897	3.9	11
1095	Increased Risk of Incident Heart Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2 Diabetes: UKPDS 89. <i>Diabetes Care</i> , 2021 , 44, 1877-1884	3.9	7
1094	Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1217-1225	3.1	39
1093	Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1477-1484	3.1	1
1092	Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. <i>Circulation</i> , 2021 , 143, 2129-2142	4.8	14

1091	Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study. <i>Circulation</i> , 2021 , 143, 2316-2318	4.8	3
1090	Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trial. <i>European Journal of Heart Failure</i> , 2021 ,	3.1	2
1089	Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial. <i>JAMA Cardiology</i> , 2021 , 6, 678-689	4	7
1088	Making the Case for an Expanded Indication for Sacubitril/Valsartan in Heart Failure. <i>Journal of Cardiac Failure</i> , 2021 , 27, 693-695	1	3
1087	Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. <i>Journal of Cardiac Failure</i> , 2021 , 27, 670-676	1	3
1086	Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1518-1524	3.1	7
1085	Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2021 , 6, 1130-1143	4	26
1084	Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1334-1349	1.2	1
1083	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 1298-1305	4	2
1082	Effect of Nephilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction. <i>Circulation</i> , 2021 , 144, 199-209	4.8	14
1081	Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 97-108	3.8	25
1080	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. <i>Circulation</i> , 2021 , 143, 298-309	4.8	69
1079	Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. <i>Circulation</i> , 2021 , 143, 438-448	4.8	36
1078	SOLOIST-WHF and updated meta-analysis: sodium-glucose co-transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure. <i>European Journal of Heart Failure</i> , 2021 , 23, 27-30	3.1	6
1077	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021 , 384, 105-116	18	164
1076	Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. <i>ESC Heart Failure</i> , 2021 , 8, 129-138	1	6
1075	Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1234-1248	1.2	3
1074	Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study. <i>JACC: Heart Failure</i> , 2021 , 9, 146-157	2	5

1073	Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 22-31	4.9	91
1072	Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 1631-1638	1.5	0
1071	Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 561-568	1.7	6
1070	The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. <i>European Heart Journal</i> , 2021 , 42, 1199-1202	3.5	18
1069	Considering dose in pharmacological therapies for heart failure - Authors' reply. <i>Lancet, The</i> , 2021 , 397, 275	11.5	
1068	Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF. <i>JACC: Heart Failure</i> , 2021 , 9, 13-24	2	10
1067	High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis. <i>Cardiovascular Research</i> , 2021 ,	2.5	2
1066	Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF. <i>European Journal of Heart Failure</i> , 2021 , 23, 632-643	3.1	8
1065	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. <i>Journal of the American Heart Association</i> , 2021 , 10, e019238	1.4	3
1064	Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. <i>Hypertension</i> , 2021 , 77, 546-556	2.4	7
1063	Sex differences in congestive markers in patients hospitalized for acute heart failure. <i>ESC Heart Failure</i> , 2021 , 8, 1784-1795	1	2
1062	Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 776-784	3.1	3
1061	Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. <i>European Journal of Heart Failure</i> , 2021 , 23, 1662-1672	3.1	6
1060	Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. <i>American Heart Journal</i> , 2021 , 237, 45-53	1.3	2
1059	A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. <i>Kidney International</i> , 2021 , 100, 215-224	2.7	35
1058	Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron Therapy. <i>JACC: Heart Failure</i> , 2021 , 9, 518-527	2	1
1057	Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 , 32, 2352-2361	3.2	13
1056	Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2021 , 42, 3741-3752	3.5	13

1055	Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure, stroke, chronic obstructive pulmonary disease or cancer. <i>PLoS ONE</i> , 2021 , 16, e0255364	1.2	0
1054	Reply: Pneumonia and the Bigger Picture of Infection in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 760-761	3.8	
1053	Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. <i>European Heart Journal</i> , 2021 , 42, 3727-3738	3.5	22
1052	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021 , 42, 3599-3726	3.5	875
1051	Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. <i>JACC: Heart Failure</i> , 2021 , 9, 807-820	2	11
1050	Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. <i>Nature Medicine</i> , 2021 , 27, 1818-1824	15.4	7
1049	Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES. <i>European Journal of Heart Failure</i> , 2021 ,	3.1	2
1048	The genomics of heart failure: design and rationale of the HERMES consortium. <i>ESC Heart Failure</i> , 2021 ,	1	1
1047	Stroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL Trial.. <i>Kidney360</i> , 2021 , 2, 1761-1769	0.5	1
1046	Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 , 32, 2900-2911	3.2	1
1045	Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021 , 10, e022069	1.4	4
1044	Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. <i>JAMA Cardiology</i> , 2021 ,	4	4
1043	Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization. <i>Journal of Cardiac Failure</i> , 2021 , 27, 1027-1030	1	
1042	Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2021 , 9, 627-635	2	1
1041	A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. <i>Kidney International</i> , 2021 ,	2.7	9
1040	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 653-662	4.9	58
1039	Head-to-head comparison of contemporary heart failure risk scores. <i>European Journal of Heart Failure</i> , 2021 ,	3.1	4
1038	Response by Lee et al to Letter Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)". <i>Circulation</i> , 2021 , 144, e40	4.8	2

1037	The ASCEND-ND trial: Study design and participant characteristics. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	1.2	1
1036	Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial. <i>Diabetes Research and Clinical Practice</i> , 2020 , 170, 108488	1.6	3
1035	Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?. <i>Circulation: Heart Failure</i> , 2020 , 13, e007879	1.7	7
1034	Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. <i>Lancet, The</i> , 2020 , 396, 1745-1757	11.5	70
1033	The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 1595-1604	1	7
1032	Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020 , 22, 1662-1671	3.1	17
1031	Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. <i>JACC: Heart Failure</i> , 2020 , 8, 618-626	2	6
1030	Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF. <i>European Journal of Heart Failure</i> , 2020 , 22, 1247-1258	3.1	19
1029	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020 , 41, 2109-2117	3.5	42
1028	Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1644-1656	3.8	23
1027	Cardiorenal risk reduction guidance in diabetes: can we reach consensus?. <i>Lancet Diabetes and Endocrinology, the</i> , 2020 , 8, 357-360	4.9	8
1026	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 1353-1368	7.4	155
1025	Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. <i>European Journal of Heart Failure</i> , 2020 , 22, 1133-1143	3.1	8
1024	Covariate adjusted reanalysis of the I-Preserve trial. <i>Clinical Research in Cardiology</i> , 2020 , 109, 1358-1365	1.2	5
1023	Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. <i>European Heart Journal</i> , 2020 , 41, 2379-2392	3.5	80
1022	Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. <i>New England Journal of Medicine</i> , 2020 , 382, 1653-1659	18	1316
1021	Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020 , 8, 372-381	2	25
1020	Reply: Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020 , 8, 245-246	2	

1019	Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. <i>JACC: Heart Failure</i> , 2020 , 8, 811-818	2	44
1018	Reply: NT-proBNP in Heart Failure With Preserved Ejection Fraction: Quest for a Marker Reflecting the Truth. <i>JACC: Heart Failure</i> , 2020 , 8, 597-598	2	
1017	Response by Jackson et al to Letter Regarding Article, "Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF". <i>Circulation</i> , 2020 , 142, e5-e6	4.8	5
1016	Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 274-282	1.2	105
1015	Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020 , 13, e006541	1.7	31
1014	Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. <i>European Journal of Heart Failure</i> , 2020 , 22, 834-844	3.1	13
1013	Body mass index and B-lines on lung ultrasonography in chronic and acute heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 1201-1209	1	10
1012	Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib. <i>American Heart Journal</i> , 2020 , 222, 157-165	1.3	10
1011	Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. <i>European Journal of Heart Failure</i> , 2020 , 22, 848-855	3.1	9
1010	βAdrenoreceptor Autoantibodies in Heart Failure: Physiology and Therapeutic Implications. <i>Circulation: Heart Failure</i> , 2020 , 13, e006155	1.7	12
1009	Quantification of pleural effusions on thoracic ultrasound in acute heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020 , 9, 513-521	0.7	3
1008	Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. <i>JAMA Cardiology</i> , 2020 , 5, 432-441	4	22
1007	Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions. <i>Circulation</i> , 2020 , 141, 843-862	4.8	25
1006	Dyslipidaemia, a factor worthy of adjustment: reply. <i>European Journal of Heart Failure</i> , 2020 , 22, 564-565	3.1	
1005	Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF. <i>JACC: Heart Failure</i> , 2020 , 8, 329-340	2	61
1004	Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. <i>Diabetes Care</i> , 2020 , 43, 1077-1084	3.9	13
1003	The prevalence and importance of frailty in heart failure with reduced ejection fraction – an analysis of PARADIGM-HF and ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2020 , 22, 2123-2133	3.1	22
1002	Endpoints in Heart Failure Drug Development: History and Future. <i>JACC: Heart Failure</i> , 2020 , 8, 429-440	2	16

1001	Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort. <i>European Journal of Heart Failure</i> , 2020 , 22, 1777-1785	3.1	19
1000	Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and end-stage renal disease. <i>European Journal of Heart Failure</i> , 2020 , 22, 813-820	3.1	2
999	Chagas disease: still a neglected emergency?. <i>Lancet, The</i> , 2020 , 395, 1113-1114	11.5	3
998	Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction. <i>European Heart Journal</i> , 2020 , 41, 2353-2355	3.5	13
997	A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. <i>European Heart Journal</i> , 2020 , 41, 2356-2362	3.5	21
996	How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020 , 40, 506-522	2.7	20
995	The year in cardiology 2019: heart failure. <i>Revista Romana De Cardiologie</i> , 2020 , 30, 185-204	0	
994	Comparison of Troponin Elevation, Prior Myocardial Infarction, and Chest Pain in Acute Ischemic Heart Failure. <i>CJC Open</i> , 2020 , 2, 135-144	0.5	3
993	Use of the Win Ratio in Cardiovascular Trials. <i>JACC: Heart Failure</i> , 2020 , 8, 441-450	2	13
992	Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. <i>Lancet, The</i> , 2020 , 396, 121-128	11.5	133
991	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,	1.2	2
990	Effects of apixaban compared with warfarin as gain in event-free time - a novel assessment of the results of the ARISTOTLE trial. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 1311-1319	1.2	1
989	Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. <i>Nature Communications</i> , 2020 , 11, 163	5	140
988	Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2020 , 8, 188-198	2	20
987	Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2020 , 22, 1402-1411	3.1	10
986	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. <i>Circulation</i> , 2020 , 141, 100-111	4.8	68
985	Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial. <i>Circulation</i> , 2020 , 141, 90-99	4.8	130
984	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Circulation</i> , 2020 , 141, 338-351	4.8	122

983	Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. <i>Circulation</i> , 2020 , 141, 352-361	4.8	145
982	Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 245-254	3.8	41
981	The year in cardiology: heart failure. <i>European Heart Journal</i> , 2020 , 41, 1232-1248	3.5	7
980	Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial. <i>Journal of Hypertension</i> , 2020 , 38, 420-425	0.5	5
979	Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020 , 22, 528-538	3.1	16
978	Estimating the Lifetime Benefits of Treatments for Heart Failure. <i>JACC: Heart Failure</i> , 2020 , 8, 984-995	2	2
977	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , 2020 , 22, 2160-2171	3.1	24
976	Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis. <i>JACC: Heart Failure</i> , 2020 , 8, 844-855	2	18
975	Sacubitril/Valsartan: Nephilysin Inhibition 5 Years After PARADIGM-HF. <i>JACC: Heart Failure</i> , 2020 , 8, 800-810	24	
974	Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM-HF. <i>ESC Heart Failure</i> , 2020 , 7, 3355	1	3
973	Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. <i>Cardiovascular Diabetology</i> , 2020 , 19, 175	2.5	1
972	Dapagliflozin in Patients with Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2020 , 383, 1436-1446	865	
971	Reply: The PARAGON-HF Trial: Toward Extension to Patients With HF Middle Range Ejection Fraction. <i>JACC: Heart Failure</i> , 2020 , 8, 698-699	2	
970	BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: Preliminary findings from UK biobank. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020 , 14, 1149-1151	3.2	49
969	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>Circulation</i> , 2020 , 142, 1040-1054	4.8	52
968	Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 2368-2378	3.8	16
967	Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study. <i>Circulation: Heart Failure</i> , 2020 , 13, e007814	1.7	5
966	Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure: The COSMIC-HF Trial. <i>Circulation: Heart Failure</i> , 2020 , 13, e008007	1.7	1

965	Risk stratification scores for patients with acute heart failure in the Emergency Department: A systematic review. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020 , 9, 375-398	0.7	11
964	Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2020 , 22, 2370-2379	3.1	9
963	Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. <i>European Journal of Heart Failure</i> , 2020 , 22, 2147-2156	3.1	41
962	Angiotensin receptor-neprilysin inhibition in heart failure with preserved ejection fraction: lessons from PARAGON-HF. <i>European Journal of Heart Failure</i> , 2020 , 22, 1525-1530	3.1	2
961	Randomized Trials Versus Common Sense and Clinical Observation: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 580-589	3.8	22
960	Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 503-514	3.8	27
959	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 1700-1711	1.2	52
958	Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. <i>Diabetes Care</i> , 2020 , 43, 2878-2881	3.9	8
957	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. <i>Circulation</i> , 2020 , 142, 1623-1632	4.8	20
956	NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2020 , 9, e017462	1.4	15
955	EMPEROR-Reduced: confirming sodium-glucose co-transporter 2 inhibitors as an essential treatment for patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020 , 22, 1987-1990	3.1	6
954	Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. <i>Circulation</i> , 2020 , 142, 1205-1218	4.8	16
953	Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. <i>European Journal of Heart Failure</i> , 2020 , 22, 2093-2101	3.1	15
952	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. <i>European Heart Journal</i> , 2020 , 41, 3787-3797	3.5	35
951	Angiotensin-Nepriylsin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020 , 142, 1236-1245	4.8	32
950	Serum potassium in the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2020 , 22, 2056-2064	3.1	14
949	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). <i>European Heart Journal</i> , 2020 , 41, 3402-3418	3.5	40
948	Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from COVID-19: systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,	1.2	20

947	Optimizing heart failure treatment following cardiac resynchronization therapy. <i>Clinical Research in Cardiology</i> , 2020 , 109, 638-645	1.2	8
946	Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 898-901	3.1	25
945	Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms. <i>Circulation</i> , 2020 , 142, 4-6	4.8	375
944	Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 1118-1127	3.2	33
943	Reply: Different Phenotype Characterization in PARAGON-HF: An Unresolved Puzzle in Patients With HFpEF. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1501-1502	3.8	
942	Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non-sudden cardiac death in myocardial infarction survivors with heart failure. <i>European Journal of Heart Failure</i> , 2019 , 21, 1248-1258	3.1	15
941	The importance of randomised vs non-randomised trials - Authors' reply. <i>Lancet, The</i> , 2019 , 394, 635	11.5	5
940	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet, The</i> , 2019 , 394, 1169-1180	11.5	106
939	Angiotensin-Nepriylsin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2019 , 381, 1609-1620	18	705
938	Temporal Trends and Patterns in Mortality After Incident Heart Failure: A Longitudinal Analysis of 86 000 Individuals. <i>JAMA Cardiology</i> , 2019 , 4, 1102-1111	4	45
937	Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. <i>Circulation</i> , 2019 , 140, 1369-1379	4.8	28
936	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2019 , 381, 1995-2008	18	2021
935	Lung Ultrasound in Acute Heart Failure: Prevalence of Pulmonary Congestion and Short- and Long-Term Outcomes. <i>JACC: Heart Failure</i> , 2019 , 7, 849-858	2	65
934	PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction. <i>Cardiovascular Research</i> , 2019 , 115, e136-e139	2.5	2
933	Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1199-1208	1.7	51
932	Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure. <i>European Journal of Heart Failure</i> , 2019 , 21, 844-851	3.1	47
931	Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2019 , 21, 1022-1031	3.1	14
930	Higher Body Mass Index in Adolescence Predicts Cardiomyopathy Risk in Midlife. <i>Circulation</i> , 2019 , 140, 117-125	4.8	25

929	Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 2101-2112	7.4	29
928	Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure: A cohort study of 93,000 UK patients. <i>PLoS Medicine</i> , 2019 , 16, e1002805	3.6	16
927	Estimated Long-Term Survival With Eplerenone. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2357-2359	3.8	5
926	Outcomes and Effect of Treatment According to Etiology in HFref: An Analysis of PARADIGM-HF. <i>JACC: Heart Failure</i> , 2019 , 7, 457-465	2	54
925	Dilated cardiomyopathy. <i>Nature Reviews Disease Primers</i> , 2019 , 5, 32	16.4	143
924	Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019 , 7, 418-427	2	10
923	A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). <i>European Journal of Heart Failure</i> , 2019 , 21, 665-675	3.1	145
922	"Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry. <i>Cardiovascular Drugs and Therapy</i> , 2019 , 33, 315-322	1.1	17
921	B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1264-1272	3.8	79
920	N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. <i>Circulation: Heart Failure</i> , 2019 , 12, e005766	1.7	14
919	Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis. <i>Heart</i> , 2019 , 105, 1325-1334	1.3	17
918	Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it. <i>European Journal of Heart Failure</i> , 2019 , 21, 699-702	3.1	5
917	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2019 , 393, 1937-1947	11.5	209
916	Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative. <i>Clinical Research in Cardiology</i> , 2019 , 108, 1215-1225	1.2	10
915	Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2019 , 25, 703-711	1	6
914	Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFref. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 795-806	3.8	82
913	Income Inequality and Outcomes in Heart Failure: A Global Between-Country Analysis. <i>JACC: Heart Failure</i> , 2019 , 7, 336-346	2	42
912	Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 337-341	3.1	69

911	Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2019 , 108, 868-877	1.2	9
910	T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF. <i>Clinical Research in Cardiology</i> , 2019 , 108, 133-141	1.2	4
909	Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction. <i>International Journal of Cardiology</i> , 2019 , 281, 179-185	0.8	5
908	High-Sensitivity Troponin T and Incident Heart Failure in Older Men: British Regional Heart Study. <i>Journal of Cardiac Failure</i> , 2019 , 25, 230-237	1	9
907	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 776-785	4.9	522
906	Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2019 , 8, e013114	1.4	38
905	Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction. <i>Korean Circulation Journal</i> , 2019 , 49, 469-484	0.6	12
904	Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction. <i>Diabetes Care</i> , 2019 , 42, 1792-1799	3.9	25
903	The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. <i>European Journal of Heart Failure</i> , 2019 , 21, 1402-1411	3.1	103
902	Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2019 , 7, 862-874	2	40
901	Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence. <i>Current Atherosclerosis Reports</i> , 2019 , 21, 41	1.7	22
900	From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5). <i>Journal of the American College of Cardiology</i> , 2019 , 74, 683-698	3.8	11
899	Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 601-612	3.8	40
898	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2019 , 21, 974-984	3.1	30
897	Winter Peaks in Heart Failure: An Inevitable or Preventable Consequence of Seasonal Vulnerability?. <i>Cardiac Failure Review</i> , 2019 , 5, 83-85	0.7	9
896	Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 345-351	3.1	28
895	Income level and inequality as complement to geographical differences in cardiovascular trials. <i>American Heart Journal</i> , 2019 , 218, 66-74	1.3	12
894	Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2893-2904	3.8	17

893	Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2858-2873	3.8	55
892	MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPHASIS-HF, and TOPCAT. <i>JACC: Heart Failure</i> , 2019 , 7, 1012-1021	2	14
891	Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019 , 12, e006539	1.7	36
890	Baseline Characteristics of the VANISH Cohort. <i>Circulation: Heart Failure</i> , 2019 , 12, e006231	1.7	5
889	Prevalence and profile of "seasonal frequent flyers" with chronic heart disease: Analysis of 1598 patients and 4588 patient-years follow-up. <i>International Journal of Cardiology</i> , 2019 , 279, 126-132	0.8	2
888	Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate. <i>Clinical Research in Cardiology</i> , 2019 , 108, 806-814	1.2	5
887	Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2019 , 73, 309-315	2.2	15
886	Real-world studies no substitute for RCTs in establishing efficacy. <i>Lancet, The</i> , 2019 , 393, 210-211	11.5	56
885	Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 29-40	3.8	86
884	Response by Claggett et al to Letter Regarding Article, "Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials". <i>Circulation</i> , 2019 , 139, 422-423	4.8	
883	Diabetic cardiomyopathy. <i>Heart</i> , 2019 , 105, 337-345	1.3	37
882	Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. <i>New England Journal of Medicine</i> , 2019 , 380, 447-458	18	187
881	Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. <i>European Journal of Heart Failure</i> , 2019 , 21, 577-587	3.1	22
880	The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. <i>European Journal of Heart Failure</i> , 2019 , 21, 40-49	3.1	31
879	Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials. <i>Clinical Research in Cardiology</i> , 2019 , 108, 477-486	1.2	39
878	Editor's Choice- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 231-241	0.7	16
877	World Heart Federation Roadmap for Heart Failure. <i>Global Heart</i> , 2019 , 14, 197-214	1.1	33
876	Reply: Time for an "Atrial-Watchful" Approach for Heart Failure Patients With a Cardiac Implantable Electronic Device. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1188-1189	3.8	

875	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. <i>Circulation</i> , 2018 , 137, 961-972	4.8	175
874	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018 , 20, 853-872	3.1	264
873	Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. <i>European Journal of Heart Failure</i> , 2018 , 20, 888-895	3.1	65
872	Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. <i>European Journal of Heart Failure</i> , 2018 , 20, 1139-1145	3.1	26
871	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1021-1034	3.8	122
870	Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 547-554	4.9	89
869	Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. <i>JAMA Cardiology</i> , 2018 , 3, 498-505	4	57
868	Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction. <i>Diabetes Care</i> , 2018 , 41, 1285-1291	3.9	23
867	Baseline characteristics and enrichment results from the SONAR trial. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1829-1835	1.7	22
866	Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. <i>JACC: Heart Failure</i> , 2018 , 6, 489-498	2	138
865	Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). <i>Circulation: Heart Failure</i> , 2018 , 11, 1015-1020	1.7	34
864	Relation of High Serum Bilirubin to Short-Term Mortality Following a Myocardial Infarction Complicated by Left Ventricular Systolic Dysfunction (from the High-Risk Myocardial Infarction Database Initiative). <i>American Journal of Cardiology</i> , 2018 , 121, 1015-1020	0.7	10
863	Hyporesponsiveness to Darbeoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbeoetin Alfa in Heart Failure): Clinical and Prognostic Associations. <i>Circulation: Heart Failure</i> , 2018 , 11, e004431	1.7	7
862	Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1369-1376	1.7	49
861	Reply: Vildagliptin and Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: One Step Forward. <i>JACC: Heart Failure</i> , 2018 , 6, 178	2	
860	Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. <i>European Journal of Heart Failure</i> , 2018 , 20, 1230-1239	3.1	159
859	Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 727-735	3.8	18
858	Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). <i>European Journal of Heart Failure</i> , 2018 , 20, 760-768	3.1	44

857	Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. <i>Heart</i> , 2018 , 104, 1006-1013	1.3	28
856	Heart Failure: Epidemiology, Pathophysiology, and Management of Heart Failure in Diabetes Mellitus. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018 , 47, 117-135	1.2	16
855	Indications and practical approach to non-invasive ventilation in acute heart failure. <i>European Heart Journal</i> , 2018 , 39, 17-25	3.5	65
854	Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction Database Initiative. <i>European Journal of Heart Failure</i> , 2018 , 20, 888-897	3.1	11
853	Microvascular complications in diabetes patients with heart failure and reduced ejection fraction-insights from the Beta-blocker Evaluation of Survival Trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 1549-1556	3.1	11
852	Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials. <i>Circulation</i> , 2018 , 138, 570-577	4.8	38
851	Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. <i>JACC: Heart Failure</i> , 2018 , 6, 564-569	2	18
850	Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist. <i>Circulation</i> , 2018 , 137, 1218-1220	4.8	14
849	Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. <i>European Heart Journal</i> , 2018 , 39, 26-35	3.5	245
848	Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2018 , 3, 164-168	4	51
847	Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. <i>European Journal of Heart Failure</i> , 2018 , 20, 268-277	3.1	25
846	Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial. <i>JACC: Heart Failure</i> , 2018 , 6, 8-17	2	96
845	Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 479-487	1.7	216
844	Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 136-147	3.1	15
843	Barcelona Bio-HF Calculator Version 2.0: incorporation of angiotensin II receptor blocker neprilysin inhibitor (ARNI) and risk for heart failure hospitalization. <i>European Journal of Heart Failure</i> , 2018 , 20, 938-940	3.1	14
842	Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?. <i>European Journal of Heart Failure</i> , 2018 , 20, 317-322	3.1	14
841	Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. <i>European Journal of Heart Failure</i> , 2018 , 20, 295-303	3.1	41
840	Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants. <i>American Heart Journal</i> , 2018 , 199, 170-175	1.3	4

839	Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3.25 Million People With and Without Diabetes Mellitus. <i>Circulation</i> , 2018 , 138, 2774-2786	4.8	78
838	Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics. <i>American Heart Journal</i> , 2018 , 203, 30-38	1.3	29
837	Initiation of domiciliary care and nursing home admission following first hospitalization of heart failure patients: a nationwide cohort study. <i>Clinical Epidemiology</i> , 2018 , 10, 917-930	1	4
836	Association is not causation: treatment effects cannot be estimated from observational data in heart failure. <i>European Heart Journal</i> , 2018 , 39, 3417-3438	3.5	29
835	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018 , 11, e004962	1.7	70
834	Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns. <i>Circulation: Heart Failure</i> , 2018 , 11, e004926	1.7	13
833	N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2899-2904	1.7	7
832	Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. <i>Circulation</i> , 2018 , 138, 1505-1514	4.8	79
831	Relationship between baseline physical activity assessed by pedometer count and new-onset diabetes in the NAVIGATOR trial. <i>BMJ Open Diabetes Research and Care</i> , 2018 , 6, e000523	1.5	23
830	Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). <i>Circulation: Heart Failure</i> , 2018 , 11, e004446	1.7	37
829	Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study. <i>ESC Heart Failure</i> , 2018 , 5, 1052-1059	1	1
828	Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). <i>American Journal of Cardiology</i> , 2018 , 122, 1506-1512	0.7	11
827	SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. <i>Diabetologia</i> , 2018 , 61, 2108-2117	2.4	381
826	Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. <i>PLoS Medicine</i> , 2018 , 15, e1002541	3.6	60
825	Anticoagulation, atherothrombosis, and heart failure: lessons from COMMANDER-HF and CORONA. <i>European Heart Journal</i> , 2018 ,	3.5	2
824	Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial. <i>Diabetologia</i> , 2018 , 61, 581-588	2.4	10
823	Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. <i>Lancet, The</i> , 2018 , 391, 572-580	11.5	421
822	Evidence-Based Therapy and Its Association With Workforce Detachment After First Hospitalization for Heart Failure. <i>JACC: Heart Failure</i> , 2018 , 6, 41-48	2	1

821	Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. <i>European Journal of Heart Failure</i> , 2018 , 20, 514-522	3.1	20
820	Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2018 , 20, 504-510	3.1	37
819	Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. <i>Heart</i> , 2018 , 104, 144-150	1.3	25
818	Employment status at time of first hospitalization for heart failure is associated with a higher risk of death and rehospitalization for heart failure. <i>European Journal of Heart Failure</i> , 2018 , 20, 240-247	3.1	12
817	Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. <i>European Journal of Heart Failure</i> , 2018 , 20, 491-500	3.1	37
816	Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration. <i>Journal of Diabetes Research</i> , 2018 , 2018, 1631263	1.1	13
815	Who Benefits From a Defibrillator-Balancing the Risk of Sudden Versus Non-sudden Death. <i>Current Heart Failure Reports</i> , 2018 , 15, 376-389	1	2
814	Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Nepriylsin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. <i>JAMA Cardiology</i> , 2018 , 3, 1226-1231	4	20
813	Talking to patients with heart failure about end of life. <i>European Journal of Heart Failure</i> , 2018 , 20, 1763-1765	3.1	5
812	Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: "Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial" by Bocchi et al. <i>ESC Heart Failure</i> , 2018 , 5, 1669-1671	1	12
811	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2018 , 392, 1519-1529	11.5	771
810	Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2018 , 24, 512-519	1	7
809	Heart Failure With Preserved Ejection Fraction in the Young. <i>Circulation</i> , 2018 , 138, 2763-2773	4.8	29
808	IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Nepriylsin Inhibition in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2018 , 11, e005133	1.7	16
807	Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data. <i>American Journal of Nephrology</i> , 2018 , 48, 260-268	1.1	21
806	Redefining heart failure phenotypes based on ejection fraction. <i>European Journal of Heart Failure</i> , 2018 , 20, 1634-1635	3.1	6
805	Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. <i>European Journal of Heart Failure</i> , 2018 , 20, 1601-1610	3.1	20
804	Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 1701-1709	3.1	34

803	Risk stratification according to insulin type: reply. <i>European Journal of Heart Failure</i> , 2018 , 20, 1498	3.1	1
802	Visit-to-visit blood pressure variation is associated with outcomes in a U-shaped fashion in patients with myocardial infarction complicated with systolic dysfunction and/or heart failure: findings from the EPHEBUS and OPTIMAAL trials. <i>Journal of Hypertension</i> , 2018 , 36, 1736-1742	0.5	7
801	Which patients with heart failure should receive specialist palliative care?. <i>European Journal of Heart Failure</i> , 2018 , 20, 1338-1347	3.1	38
800	European Society of Cardiology-Acute Cardiovascular Care Association Position paper on acute heart failure: A call for interdisciplinary care. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017 , 6, 81-86	0.7	34
799	European Society of Cardiology - Acute Cardiovascular Care Association position paper on safe discharge of acute heart failure patients from the emergency department. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017 , 6, 311-320	0.7	42
798	Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). <i>Biomarkers</i> , 2017 , 22, 261-267	0.9	6
797	International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	1.4	4
796	Clinical Trials Involving Hypertension. <i>New England Journal of Medicine</i> , 2017 , 376, 290	18	6
795	Effect of valsartan on kidney outcomes in people with impaired glucose tolerance. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 791-799	1.7	6
794	Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. <i>Journal of the American Heart Association</i> , 2017 , 6,	1.4	2
793	Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS. <i>Revista Espanola De Cardiologia</i> , 2017 , 70, 50.e1-50.e84	0.3	6
792	Referral for Specialist Follow-up and Its Association With Post-discharge Mortality Among Patients With Systolic Heart Failure (from the National Heart Failure Audit for England and Wales). <i>American Journal of Cardiology</i> , 2017 , 119, 440-444	0.7	16
791	Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis. <i>Circulation: Heart Failure</i> , 2017 , 10,	1.7	109
790	Variation in hospital performance for heart failure management in the National Heart Failure Audit for England and Wales. <i>Heart</i> , 2017 , 103, 55-62	1.3	11
789	Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction: A Meta-Analysis of Published Study Data. <i>Circulation: Heart Failure</i> , 2017 , 10,	1.7	55
788	The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial. <i>American Heart Journal</i> , 2017 , 187, 145-155	1.3	33
787	Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS). <i>European Journal of Heart Failure</i> , 2017 , 19, 739-747	3.1	21
786	Serum Chloride and Sodium Interplay in Patients With Acute Myocardial Infarction and Heart Failure With Reduced Ejection Fraction: An Analysis From the High-Risk Myocardial Infarction Database Initiative. <i>Circulation: Heart Failure</i> , 2017 , 10,	1.7	28

785	Updated risk factors should be used to predict development of diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 859-863	0.9	2
784	Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. <i>New England Journal of Medicine</i> , 2017 , 376, 1956-1964	18	185
783	Cognitive Impairment and Heart Failure: Systematic Review and Meta-Analysis. <i>Journal of Cardiac Failure</i> , 2017 , 23, 464-475	1	140
782	Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials. <i>JACC: Heart Failure</i> , 2017 , 5, 317-326	2	57
781	Expert consensus document: Echocardiography and lung ultrasonography for the assessment and management of acute heart failure. <i>Nature Reviews Cardiology</i> , 2017 , 14, 427-440	4.9	84
780	Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure. <i>Lancet, The</i> , 2017 , 389, 1831-1840 ³⁷	11.5	37
779	Seasonal variations in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2017 , 14, 654-664	4.9	92
778	Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. <i>Cardiovascular Drugs and Therapy</i> , 2017 , 31, 295-301	1.1	2
777	The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure. <i>JAMA Cardiology</i> , 2017 , 2, 939-940	4	104
776	Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: a systematic review. <i>European Journal of Heart Failure</i> , 2017 , 19, 1154-1163	3.1	101
775	Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2017 , 6,	1.4	45
774	ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2017 , 70, 522-531	2.2	7
773	EFFECT OF SACUBITRIL/VALSARTAN COMPARED WITH ENALAPRIL, ACCORDING TO ETIOLOGY IN PARADIGM-HF. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 919	3.8	4
772	Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. <i>European Heart Journal</i> , 2017 , 38, 1132-1143	3.5	109
771	New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. <i>European Journal of Heart Failure</i> , 2017 , 19, 718-727	3.1	15
770	Limited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2017 , 5, 256-264	2	21
769	Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2017 , 2, 525-534	4	13
768	Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. <i>European Journal of Heart Failure</i> , 2017 , 19, 1186-1197	3.1	55

767	The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. <i>American Heart Journal</i> , 2017 , 188, 35-41	1.3	24
766	Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 333-340	4.9	164
765	Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). <i>Circulation</i> , 2017 , 135, 724-735	4.8	100
764	Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. <i>Cardiovascular Drugs and Therapy</i> , 2017 , 31, 545-549	1.1	35
763	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2017 , 10,	1.7	37
762	Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017 , 136, 1560-1562	4.8	5
761	How robust are clinical trials in heart failure?. <i>European Heart Journal</i> , 2017 , 38, 338-345	3.5	37
760	Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. <i>European Heart Journal</i> , 2017 , 38, 742-750	3.5	25
759	Mind the Gap: Current Challenges and Future State of Heart Failure Care. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1434-1449	1.3	13
758	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 877-886	4.9	164
757	Heart Failure in Young Adults Is Associated With High Mortality: A Contemporary Population-Level Analysis. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1472-1477	1.3	17
756	Re-Examination of the BEST Trial Using Composite Outcomes, Including Emergency Department Visits. <i>JACC: Heart Failure</i> , 2017 , 5, 591-599	2	10
755	Health-Related Quality of Life Outcomes in PARADIGM-HF. <i>Circulation: Heart Failure</i> , 2017 , 10,	1.7	91
754	Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. <i>American Journal of Nephrology</i> , 2017 , 46, 488-497	1.1	5
753	Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2017 , 10,	1.7	34
752	Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 2490-2500	3.8	65
751	Reply: An Opportunity to Definitively Evaluate the Theoretical Risks of Neprilysin Inhibition. <i>JACC: Heart Failure</i> , 2017 , 5, 852-853	2	1
750	Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2017 , 5, 471-482	2	176

749	Cost-Effectiveness Analysis of Natriuretic Peptide Testing and Specialist Management in Patients with Suspected Acute Heart Failure. <i>Value in Health</i> , 2017 , 20, 1025-1033	0.9	6
748	Declining Risk of Sudden Death in Heart Failure. <i>New England Journal of Medicine</i> , 2017 , 377, 41-51	18	232
747	B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review. <i>BMC Pulmonary Medicine</i> , 2017 , 17, 11	1	27
746	Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. <i>JAMA Cardiology</i> , 2017 , 2, 79-85	4	84
745	Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. <i>European Journal of Heart Failure</i> , 2017 , 19, 792-799	3.1	28
744	Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2017 , 23, 20-28	1	20
743	Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2017 , 19, 129-137	3.1	68
742	Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2017 , 19, 673-681	3.1	28
741	Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. <i>European Journal of Heart Failure</i> , 2017 , 19, 241-249	3.1	15
740	Sacubitril/Valsartan (LCZ696) in Heart Failure. <i>Handbook of Experimental Pharmacology</i> , 2017 , 243, 133-168		15
739	Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). <i>European Heart Journal</i> , 2017 , 38, 1843-1850	3.5	42
738	Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016 , 109, 377-382	1	24
737	Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia--the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). <i>Journal of Human Hypertension</i> , 2016 , 30, 46-52	0.9	9
736	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016 , 37, 2893-2962	3.5	4465
735	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>Europace</i> , 2016 , 18, 1609-1678	1	1293
734	Aliskiren, Enalapril, or Both in Heart Failure. <i>New England Journal of Medicine</i> , 2016 , 375, 702	18	4
733	Return to the Workforce After First Hospitalization for Heart Failure: A Danish Nationwide Cohort Study. <i>Circulation</i> , 2016 , 134, 999-1009	4.8	29
732	Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2425-2436	3.8	190

731	Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2488-2490	3.8	4
730	Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy. <i>Circulation: Heart Failure</i> , 2016 , 9,	4.8	28
729	The Effect of Omecamtiv Mecarbil on Symptoms of Heart Failure in the Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF). <i>Journal of Cardiac Failure</i> , 2016 , 22, S10-S11	1	3
728	Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy. <i>Circulation: Heart Failure</i> , 2016 , 9,	1.7	53
727	Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. <i>European Journal of Heart Failure</i> , 2016 , 18, 1162-71	3.1	21
726	C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2016 , 68, 873-881	2.2	21
725	Practical approach on frail older patients attended for acute heart failure. <i>International Journal of Cardiology</i> , 2016 , 222, 62-71	0.8	25
724	Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. <i>European Journal of Heart Failure</i> , 2016 , 18, 1238-1243	3.1	44
723	Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 241-248	3.8	81
722	Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. <i>European Journal of Heart Failure</i> , 2016 , 18, 1508-1517	3.1	41
721	The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. <i>Heart</i> , 2016 , 102, 1342-7	1.3	91
720	Lessons in Uncertainty and Humility - Clinical Trials Involving Hypertension. <i>New England Journal of Medicine</i> , 2016 , 375, 1756-1766	18	15
719	Clinical Trials Series. <i>New England Journal of Medicine</i> , 2016 , 374, 2167-2167	18	14
718	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2016 , 117, 1771-8	0.7	23
717	Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. <i>European Stroke Journal</i> , 2016 , 1, 93-100	1.5	
716	Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. <i>Circulation: Heart Failure</i> , 2016 , 9,	1.7	35
715	Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study. <i>European Journal of Heart Failure</i> , 2016 , 18, 1175-81	3.1	11
714	Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2016 , 1, 666-72	4	86

713	Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. <i>Circulation: Heart Failure</i> , 2016 , 9,	1.7	201
712	Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2016 , 4, 309-17	4.9	31
711	Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , 2016 , 4, 68-77	2	32
710	Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. <i>Circulation: Heart Failure</i> , 2016 , 9,	1.7	68
709	Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1444-1455	3.8	142
708	Dichotomous Relationship Between Age and 30-Day Death or Rehospitalization in Heart Failure Patients Admitted With Acute Decompensated Heart Failure: Results From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2016 , 22, 409-16	1	3
707	Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial. <i>International Journal of Cardiology</i> , 2016 , 209, 310-6	0.8	19
706	Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. <i>Circulation: Heart Failure</i> , 2016 , 9, e002744	1.7	100
705	Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. <i>JACC: Heart Failure</i> , 2016 , 4, 152-158	2	73
704	Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS. <i>Journal of Cardiac Failure</i> , 2016 , 22, 815-22	1	21
703	Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction. <i>European Heart Journal</i> , 2016 , 37, 466-72	3.5	22
702	Predicting heart failure decompensation using cardiac implantable electronic devices: a review of practices and challenges. <i>European Journal of Heart Failure</i> , 2016 , 18, 977-86	3.1	35
701	Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2016 , 18, 328-36	3.1	62
700	Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>Journal of the American Heart Association</i> , 2016 , 5,	1.4	17
699	Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 169-77	1.7	44
698	The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2016 , 18, 306-13	3.1	26
697	Geographic variations in the PARADIGM-HF heart failure trial. <i>European Heart Journal</i> , 2016 , 37, 3167-3174	3.4	88
696	Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial. <i>JACC: Heart Failure</i> , 2016 , 4, 816-822	2	58

695	Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2016 , 18, 424-32	3.1	28
694	Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. <i>European Journal of Heart Failure</i> , 2016 , 18, 1021-31	3.1	13
693	The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. <i>European Journal of Heart Failure</i> , 2016 , 18, 1491-1498	3.1	41
692	Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2016 , 388, 2895-2903	11.5	158
691	Renal function estimation and Cockcroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart 'OMics' in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. <i>BMC Medicine</i> 2016 , 14, 181	2.9	35
690	Predicting Outcomes Over Time in Patients With Heart Failure, Left Ventricular Systolic Dysfunction, or Both Following Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2016 , 5,	1.4	1
689	Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. <i>Revista Espanola De Cardiologia</i> , 2016 , 69, 1167.e1-1167.e85	0.3	91
688	Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. <i>New England Journal of Medicine</i> , 2016 , 374, 1521-32	18	159
687	Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). <i>Circulation</i> , 2016 , 133, 2254-62	4.8	96
686	SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?. <i>Diabetologia</i> , 2016 , 59, 1333-1339	2.4	207
685	Reporting of Lost to Follow-Up and Treatment Discontinuation in Pharmacotherapy and Device Trials in Chronic Heart Failure: A Systematic Review. <i>Circulation: Heart Failure</i> , 2016 , 9,	1.7	7
684	Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis. <i>JACC: Heart Failure</i> , 2016 , 4, 870-880	2	41
683	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2016 , 50, e1-e88	0.6	589
682	Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2016 , 18, 1228-1234	3.1	118
681	Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. <i>European Journal of Heart Failure</i> , 2016 , 18, 290-7	3.1	33
680	Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. <i>European Journal of Heart Failure</i> , 2016 , 18, 482-9	3.1	49
679	Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. <i>European Journal of Heart Failure</i> , 2016 , 18, 1193-202	3.1	135
678	Telomere length and outcomes in ischaemic heart failure: data from the COntrolled ROsuvastatin multiNATIONAL Trial in Heart Failure (CORONA). <i>European Journal of Heart Failure</i> , 2015 , 17, 313-9	3.1	12

677	Site selection for heart failure clinical trials in the USA. <i>Heart Failure Reviews</i> , 2015 , 20, 375-83	1.3	9
676	Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2015 , 17, 510-7	3.1	115
675	'Hearts and minds': association, causation and implication of cognitive impairment in heart failure. <i>Alzheimer's Research and Therapy</i> , 2015 , 7, 22	2.8	53
674	Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>European Journal of Heart Failure</i> , 2015 , 17, 301-12	3.1	37
673	Combined Free Light Chains Are Novel Predictors of Prognosis in Heart Failure. <i>JACC: Heart Failure</i> , 2015 , 3, 618-25	2	14
672	Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus. <i>American Heart Journal</i> , 2015 , 170, 322-9	1.3	30
671	Falling Cardiovascular Mortality in Heart Failure With Reduced Ejection Fraction and Implications for Clinical Trials. <i>JACC: Heart Failure</i> , 2015 , 3, 603-14	2	26
670	Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. <i>European Journal of Heart Failure</i> , 2015 , 17, 196-204	3.1	12
669	Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. <i>European Heart Journal</i> , 2015 , 36, 2310-7	3.5	20
668	Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2015 , 17, 169-76	3.1	25
667	Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. <i>European Journal of Heart Failure</i> , 2015 , 17, 434-41	3.1	29
666	Temporal trends and risk factors for readmission for infections, gastrointestinal and immobility complications after an incident hospitalisation for stroke in Scotland between 1997 and 2005. <i>BMC Neurology</i> , 2015 , 15, 3	0.9	6
665	The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction). <i>JACC: Heart Failure</i> , 2015 , 3, 429-441	2	48
664	The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. <i>BMJ, The</i> , 2015 , 350, h910	2.2	196
663	The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. <i>European Heart Journal</i> , 2015 , 36, 1536-46	3.5	88
662	Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. <i>European Journal of Heart Failure</i> , 2015 , 17, 242-7	3.1	72
661	Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials. <i>Circulation</i> , 2015 , 131, 1486-94; discussion 1494	4.8	66
660	Meta-Analysis of Large-Scale Randomized Trials to Determine the Effectiveness of Inhibition of the Renin-Angiotensin Aldosterone System in Heart Failure. <i>American Journal of Cardiology</i> , 2015 , 116, 155-61	0.7	28

659	Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. <i>American Heart Journal</i> , 2015 , 170, 290-7	1.3	41
658	Efficacy of LCZ696 Persists at Lower Than Target Doses in the PARADIGM-HF Trial. <i>Journal of Cardiac Failure</i> , 2015 , 21, S9-S10	1	6
657	Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial. <i>European Heart Journal</i> , 2015 , 36, 2463-9	3.5	25
656	Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2059-2071	3.8	87
655	Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial. <i>Circulation: Heart Failure</i> , 2015 , 8, 717-24	1.7	15
654	Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2015 , 3, 697-703	4.9	57
653	Associations of chronic heart failure with outcome in acute ischaemic stroke patients who received systemic thrombolysis: analysis from VISTA. <i>European Journal of Neurology</i> , 2015 , 22, 163-9	1.6	14
652	Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). <i>JACC: Heart Failure</i> , 2015 , 3, 777-85	2	18
651	Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. <i>European Heart Journal</i> , 2015 , 36, 2576-84	3.5	129
650	Making Sense of Statistics in Clinical Trial Reports: Part 1 of a 4-Part Series on Statistics for Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2536-49	3.8	35
649	Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2015 , 373, 2247-57	18	1393
648	Response to Letter Regarding Article, "Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca Heart Failure (GUSTO-HF) Trials". <i>Circulation</i> , 2015 , 132, 2750-2752	4.8	1
647	Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015 , 3, 478-486	2	17
646	Improving outcomes in heart failure: a personal perspective. <i>European Heart Journal</i> , 2015 , 36, 3467-70	3.5	25
645	International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. <i>Circulation</i> , 2015 , 131, 43-53	4.8	58
644	Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. <i>European Heart Journal</i> , 2015 , 36, 669-75	3.5	47
643	Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial. <i>American Journal of Medicine</i> , 2015 , 128, 297-302	0.6	6
642	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. <i>Lancet, The</i> , 2015 , 385, 351-61	11.5	409

641	Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015 , 1, 86-94	1.2	44
640	Palliative care needs in patients hospitalized with heart failure (PCHF) study: rationale and design. <i>ESC Heart Failure</i> , 2015 , 2, 25-36	1	15
639	Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. <i>European Journal of Heart Failure</i> , 2015 , 17, 809-17	3.1	45
638	Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. <i>European Journal of Heart Failure</i> , 2015 , 17, 541-50	3.1	236
637	Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). <i>European Journal of Heart Failure</i> , 2015 , 17, 707-16	3.1	15
636	The Aliskiren Trial to Minimize Outcomes in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics. <i>European Journal of Heart Failure</i> , 2015 , 17, 1075-83	3.1	16
635	Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. <i>European Journal of Heart Failure</i> , 2015 , 17, 1201-7	3.1	23
634	What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold?. <i>Open Heart</i> , 2015 , 2, e000283	0.9	11
633	Assessment and prevalence of pulmonary oedema in contemporary acute heart failure trials: a systematic review. <i>European Journal of Heart Failure</i> , 2015 , 17, 906-16	3.1	30
632	Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial. <i>Diabetic Medicine</i> , 2015 , 32, 1090-6	0.8	11
631	Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. <i>European Journal of Heart Failure</i> , 2015 , 17, 925-35	3.1	120
630	Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis. <i>European Journal of Heart Failure</i> , 2015 , 17, 1182-91	3.1	37
629	Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>PLoS ONE</i> , 2015 , 10, e0133970	1.2	17
628	Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. <i>European Heart Journal</i> , 2015 , 36, 1106-14	3.5	37
627	It is BEAUTIFUL we should be concerned about, not SIGNIFY: is ivabradine less effective in ischaemic compared with non-ischaemic LVSD?. <i>European Heart Journal</i> , 2015 , 36, 2047-2049	3.5	11
626	Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine--short version. <i>European Heart Journal</i> , 2015 , 36, 1958-66	3.5	75
625	Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. <i>European Heart Journal</i> , 2015 , 36, 1990-7	3.5	245
624	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015 , 169, 631-638.e7	1.3	72

623	The Emerging Potential of the Apelin-APJ System in Heart Failure. <i>Journal of Cardiac Failure</i> , 2015 , 21, 489-98	1	42
622	Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2015 , 66, 429-40	2.2	20
621	Ethnic-Specific Normative Reference Values for Echocardiographic LA and LV Size, LV Mass, and Systolic Function: The EchoNoRMAL Study. <i>JACC: Cardiovascular Imaging</i> , 2015 , 8, 656-65	2	125
620	Statistical Controversies in Reporting of Clinical Trials: Part 2 of a 4-Part Series on Statistics for Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2648-2662	3.8	57
619	Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. <i>New England Journal of Medicine</i> , 2015 , 373, 2289-90	18	71
618	Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study. <i>BMJ Open</i> , 2015 , 5, e007901	0.9	6
617	Predictive value of endostatin in chronic heart failure patients with poor kidney function. <i>Cardiology</i> , 2015 , 130, 17-22	0.4	14
616	Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial. <i>Journal of the American Heart Association</i> , 2015 , 4, e002092	1.4	19
615	Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. <i>JACC: Heart Failure</i> , 2015 , 3, 40-49	2	31
614	Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. <i>Circulation</i> , 2015 , 131, 54-61	4.8	430
613	Acute heart failure in the elderly: differences in clinical characteristics, outcomes, and prognostic factors in the VERITAS Study. <i>Journal of Cardiac Failure</i> , 2015 , 21, 179-88	1	47
612	Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. <i>Clinical Chemistry</i> , 2015 , 61, 368-78	1.4	29
611	Novel extracellular matrix biomarkers as predictors of adverse outcome in chronic heart failure: association between biglycan and response to statin therapy in the CORONA trial. <i>Journal of Cardiac Failure</i> , 2015 , 21, 153-9	1	10
610	Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2015 , 17, 340-6	3.1	13
609	A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. <i>European Heart Journal</i> , 2015 , 36, 434-9	3.5	66
608	Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 447-56	3.8	439
607	Developing therapies for heart failure with preserved ejection fraction: current state and future directions. <i>JACC: Heart Failure</i> , 2014 , 2, 97-112	2	213
606	Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. <i>European Journal of Heart Failure</i> , 2014 , 16, 671-7	3.1	56

605	High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>Circulation</i> , 2014 , 129, 625-34	4.8	86
604	Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis. <i>Lancet, The</i> , 2014 , 383, 1059-66	11.5	143
603	Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2014 , 2, 116-24	4.9	131
602	High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 52-61	3.8	114
601	Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). <i>European Journal of Heart Failure</i> , 2014 , 16, 817-25	3.1	119
600	A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014 , 16, 1175-82	3.1	53
599	Acute decompensated heart failure patients admitted to critical care units: insights from ASCEND-HF. <i>International Journal of Cardiology</i> , 2014 , 177, 840-6	0.8	9
598	Comorbidities and differential diagnosis in heart failure with preserved ejection fraction. <i>Heart Failure Clinics</i> , 2014 , 10, 481-501	0.9	27
597	Terminology and definition of changes renal function in heart failure. <i>European Heart Journal</i> , 2014 , 35, 3413-6	3.5	88
596	Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). <i>European Journal of Heart Failure</i> , 2014 , 16, 778-87	3.1	60
595	Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. <i>Journal of Cardiac Failure</i> , 2014 , 20, 953-8	1	115
594	Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2014 , 35, 224-32	3.5	118
593	Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial. <i>Circulation: Heart Failure</i> , 2014 , 7, 96-103	1.7	47
592	Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>European Heart Journal</i> , 2014 , 35, 3426-33	3.5	10
591	Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). <i>Circulation: Heart Failure</i> , 2014 ,	1.7	154
590	Chronic obstructive pulmonary disease and cardiovascular risk: insights from the NAVIGATOR trial. <i>International Journal of Cardiology</i> , 2014 , 176, 1126-8	0.8	8
589	Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1106-13	3.8	48
588	Risk prediction in patients with heart failure: a systematic review and analysis. <i>JACC: Heart Failure</i> , 2014 , 2, 440-6	2	209

587	Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2014 , 35, 42-7	3.5	48
586	Angiotensin-neprilysin inhibition versus enalapril in heart failure. <i>New England Journal of Medicine</i> , 2014 , 371, 993-1004	18	3301
585	Reply: does speckle tracking really improve diagnosis and risk stratification in patients with HF with normal EF?. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1535-6	3.8	
584	Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. <i>Circulation: Heart Failure</i> , 2014 , 7, 590-5	1.7	97
583	Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. <i>American Heart Journal</i> , 2014 , 168, 23-9.e2	1.3	46
582	Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 843-51	4.9	214
581	Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). <i>JACC: Heart Failure</i> , 2014 , 2, 289-97	2	84
580	Treatment of severe hypertriglyceridaemia. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 860	4.9	
579	Fatigue as a predictor of outcome in patients with heart failure: analysis of CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). <i>JACC: Heart Failure</i> , 2014 , 2, 187-97	2	24
578	Digitalis for treatment of heart failure in patients in sinus rhythm. <i>The Cochrane Library</i> , 2014 , CD002901	1.6	11
577	The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF. <i>Journal of Internal Medicine</i> , 2014 , 275, 134-43	2.9	21
576	Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). <i>European Heart Journal</i> , 2014 , 35, 2714-21	3.5	50
575	Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR. <i>Metabolism: Clinical and Experimental</i> , 2014 , 63, 554-61	2.7	27
574	Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. <i>Circulation: Heart Failure</i> , 2014 , 7, 953-9	1.7	62
573	Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF. <i>Circulation: Heart Failure</i> , 2014 , 7, 918-25	1.7	37
572	Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF). <i>Circulation</i> , 2014 , 130, 958-65	4.8	36
571	Large streamlined trials in cardiovascular disease. <i>European Heart Journal</i> , 2014 , 35, 544-8	3.5	19
570	Neprilysin inhibition for heart failure. <i>New England Journal of Medicine</i> , 2014 , 371, 2336-7	18	33

569	The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. <i>International Journal of Obesity</i> , 2014 , 38, 1110-4	1.5	123
568	Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study. <i>European Journal of Heart Failure</i> , 2014 , 16, 1362-71	3.1	22
567	Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2014 , 35, 3442-51	3.5	54
566	Heart failure care in low- and middle-income countries: a systematic review and meta-analysis. <i>PLoS Medicine</i> , 2014 , 11, e1001699	3.6	135
565	Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms. <i>Heart</i> , 2014 , 100, 1681-7	1.3	21
564	β-blockers, atrial fibrillation, and heart failure. <i>Lancet, The</i> , 2014 , 384, 2181-3	11.5	6
563	Response to letter regarding article, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation". <i>Circulation</i> , 2014 , 129, e21-2	4.8	1
562	History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. <i>Circulation: Heart Failure</i> , 2014 , 7, 960-6	1.7	28
561	Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. <i>BMJ Open</i> , 2014 , 4, e005354	0.9	64
560	EURObservational Research Programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM. <i>European Journal of Heart Failure</i> , 2014 , 16, 583-91	3.1	80
559	The association between meteorological events and acute heart failure: new insights from ASCEND-HF. <i>International Journal of Cardiology</i> , 2014 , 177, 819-24	0.8	9
558	Corrigendum to 'Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved' [<i>Eur J Heart Fail</i> 2014;16:3340]. <i>European Journal of Heart Failure</i> , 2014 , 16, 592-592	3.1	2
557	Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat. <i>Cardiovascular Therapeutics</i> , 2014 , 32, 13-8	0.8	28
556	Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome. Results from CORONA. <i>European Journal of Heart Failure</i> , 2014 , 16, 68-75	3.1	46
555	Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. <i>European Journal of Heart Failure</i> , 2014 , 16, 33-40	3.1	141
554	Microvolt T-wave alternans testing in patients recently hospitalized with decompensated heart failure. <i>European Journal of Heart Failure</i> , 2014 , 16, 113	3.1	
553	Impaired left atrial function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014 , 16, 1096-103	3.1	150
552	Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014 , 16, 535-42	3.1	137

551	The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patients. <i>European Journal of Heart Failure</i> , 2014 , 16, 289-99	3.1	15
550	Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. <i>Circulation: Heart Failure</i> , 2014 , 7, 895-902	1.7	25
549	Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. <i>BMJ Open Diabetes Research and Care</i> , 2014 , 2, e000011	1.5	21
548	Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study. <i>Diabetes, Obesity and Metabolism</i> , 2014 , 16, 1265-8	1.7	2
547	High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. <i>Journal of Cardiac Failure</i> , 2014 , 20, 319-26	1	37
546	Thyroid-stimulating hormone and clinical outcomes: the CORONA trial (controlled rosuvastatin multinational study in heart failure). <i>JACC: Heart Failure</i> , 2014 , 2, 35-40	2	21
545	Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 853-71	3.8	80
544	Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON). <i>American Journal of Nephrology</i> , 2013 , 37, 212-22	1.1	67
543	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 1495-1539	3.8	233
542	Peripheral artery disease and outcomes after myocardial infarction: an individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT. <i>International Journal of Cardiology</i> , 2013 , 168, 1094-101	0.8	34
541	Effect of rosuvastatin on fatigue in patients with heart failure. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 1121-2	3.8	6
540	Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. <i>American Journal of Medicine</i> , 2013 , 126, 701-8	0.6	42
539	Prognostic value of CXCL16 in patients with left ventricular systolic dysfunction and heart failure. <i>International Journal of Cardiology</i> , 2013 , 168, 4427-9	0.8	4
538	Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). <i>Journal of the American College of Cardiology</i> , 2013 , 61, 1008-13	3.1	264
537	2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i> , 2013 , 128, e240-327	4.8	1927
536	Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure). <i>Journal of the American College of Cardiology</i> , 2013 , 62, 1507-22	3.8	168
535	Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. <i>European Journal of Heart Failure</i> , 2013 , 15, 947-59	3.1	63
534	Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. <i>American Heart Journal</i> , 2013 , 166, 208-216.e28	1.3	19

533	Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy. <i>European Heart Journal</i> , 2013 , 34, 1621-9	3.5	8
532	Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). <i>Journal of the American College of Cardiology</i> , 2013 , 62, 1845-54	3.8	62
531	CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials. <i>European Journal of Heart Failure</i> , 2013 , 15, 747-55	3.1	9
530	Known and missing left ventricular ejection fraction and survival in patients with heart failure: a MAGGIC meta-analysis report. <i>European Journal of Heart Failure</i> , 2013 , 15, 1220-7	3.1	22
529	Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. <i>Circulation: Heart Failure</i> , 2013 , 6, 451-60	1.7	106
528	The past, present and future of renin-angiotensin aldosterone system inhibition. <i>International Journal of Cardiology</i> , 2013 , 167, 1677-87	0.8	82
527	Reply: To PMID 23141494. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 1749	3.8	
526	Results of a reevaluation of cardiovascular outcomes in the RECORD trial. <i>American Heart Journal</i> , 2013 , 166, 240-249.e1	1.3	128
525	Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. <i>American Heart Journal</i> , 2013 , 166, 935-40.e1	1.3	27
524	A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk. <i>American Journal of Cardiology</i> , 2013 , 112, 231-7	0.7	4
523	Angina and intermittent claudication in 7403 participants of the 2003 Scottish Health Survey: impact on general and mental health, quality of life and five-year mortality. <i>International Journal of Cardiology</i> , 2013 , 167, 2149-55	0.8	15
522	Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. <i>American Journal of Kidney Diseases</i> , 2013 , 61, 238-46	2.2	15
521	Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. <i>International Journal of Cardiology</i> , 2013 , 167, 1807-24	0.8	374
520	Aliskiren in type 2 diabetes and cardiorenal end points. <i>New England Journal of Medicine</i> , 2013 , 368, 1065-8	1.8	2
519	Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. <i>JACC: Heart Failure</i> , 2013 , 1, 21-8	2	97
518	Treatment of anemia with darbepoetin alfa in systolic heart failure. <i>New England Journal of Medicine</i> , 2013 , 368, 1210-9	1.8	331
517	2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2013 , 62, e147-239	3.8	4318
516	Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. <i>Circulation</i> , 2013 , 127, 2166-76	4.8	164

515	N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). <i>Journal of the American College of Cardiology</i> , 2013 , 61, 2274-84	3.8	149
514	Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. <i>New England Journal of Medicine</i> , 2013 , 369, 2492-503	18	662
513	Spectral microvolt T-wave alternans testing has no prognostic value in patients recently hospitalized with decompensated heart failure. <i>European Journal of Heart Failure</i> , 2013 , 15, 1253-61	3.1	12
512	Darbepoetin alfa in systolic heart failure. <i>New England Journal of Medicine</i> , 2013 , 369, 488-9	18	3
511	Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. <i>BMJ, The</i> , 2013 , 347, f6745	2.2	63
510	Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>Circulation: Heart Failure</i> , 2013 , 6, 91-8	1.7	37
509	Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. <i>European Heart Journal</i> , 2013 , 34, 1404-13	3.5	595
508	Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. <i>Circulation: Heart Failure</i> , 2013 , 6, 711-8	1.7	26
507	Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study. <i>Circulation: Heart Failure</i> , 2013 , 6, 203-10	1.7	24
506	Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates?: Findings from ASCEND-HF. <i>Circulation: Heart Failure</i> , 2013 , 6, 727-32	1.7	85
505	Galectin-3 and cardiac function in survivors of acute myocardial infarction. <i>Circulation: Heart Failure</i> , 2013 , 6, 492-8	1.7	83
504	Iron status in patients with chronic heart failure. <i>European Heart Journal</i> , 2013 , 34, 827-34	3.5	154
503	Response to Letter Regarding Article, Galectin-3 and Cardiac Function in Survivors of Acute Myocardial Infarction. <i>Circulation: Heart Failure</i> , 2013 , 6, e58	1.7	2
502	The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. <i>European Heart Journal</i> , 2013 , 34, 2823-9	3.5	61
501	2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i> , 2013 , 128, 1810-52	4.8	2321
500	Letter by MacDonald et al regarding article, "Catheter ablation of atrial fibrillation". <i>Circulation</i> , 2013 , 127, e433	4.8	
499	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. <i>European Journal of Heart Failure</i> , 2013 , 15, 1082-94	3.1	143
498	Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. <i>European Journal of Heart Failure</i> , 2013 , 15, 551-9	3.1	54

497	Baseline characteristics of patients in the Reduction of Events with Darbeoetin alfa in Heart Failure trial (RED-HF). <i>European Journal of Heart Failure</i> , 2013 , 15, 334-41	3.1	20
496	Baseline characteristics in the Bardoxolone methyl Evaluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal events (BEACON) trial. <i>Nephrology Dialysis Transplantation</i> , 2013 , 28, 2841-50	1.2	18
495	Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. <i>Stroke</i> , 2013 , 44, 2590-3	1.8	8
494	The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA*. <i>Journal of Internal Medicine</i> , 2012 , 271, 436-43	2.9	48
493	Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study. <i>Journal of Clinical Hypertension</i> , 2012 , 14, 731	0.6	1
492	Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. <i>Lancet, The</i> , 2012 , 380, 1749-58	11.5	150
491	Effects of dalcetrapib in patients with a recent acute coronary syndrome. <i>New England Journal of Medicine</i> , 2012 , 367, 2089-99	18	1424
490	Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. <i>European Journal of Heart Failure</i> , 2012 , 14, 185-92	3.1	33
489	What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 2349-56	3.8	136
488	The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. <i>Lancet, The</i> , 2012 , 380, 1387-95	11.5	756
487	Prediabetes and the risk of diabetes. <i>Lancet, The</i> , 2012 , 380, 1225-6; author reply 1226	11.5	5
486	Cardiorenal end points in a trial of aliskiren for type 2 diabetes. <i>New England Journal of Medicine</i> , 2012 , 367, 2204-13	18	893
485	Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. <i>European Journal of Heart Failure</i> , 2012 , 14, 268-77	3.1	92
484	Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction. <i>Journal of the American Society of Echocardiography</i> , 2012 , 25, 535-42	1.1	25
483	Profile of microvolt T-wave alternans testing in 1003 patients hospitalized with heart failure. <i>European Journal of Heart Failure</i> , 2012 , 14, 377-86	3.1	18
482	Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta-analysis. <i>European Journal of Heart Failure</i> , 2012 , 14, 473-9	3.1	119
481	Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). <i>European Journal of Heart Failure</i> , 2012 , 14, 909-15	3.1	48
480	Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. <i>European Journal of Heart Failure</i> , 2012 , 14, 1257-64	3.1	82

479	Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction. <i>European Heart Journal</i> , 2012 , 33, 314-24	3.5	72
478	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by independent experts. Developed with the special contribution of the European Association of Cardiovascular Prevention & Rehabilitation (EACPR). <i>Eur Heart J</i> 2011; 33: 2312-1001. doi: 10.1093/eurheart/ehs092. <i>European Heart Journal</i> , 2012 , 33, 2125-126	3.5	2797
477	'European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)' The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by independent experts. Developed with the special contribution of the European Association of Cardiovascular Prevention & Rehabilitation (EACPR). <i>Eur Heart J</i> 2011; 33: 2312-1001. doi: 10.1093/eurheart/ehs092. <i>European Heart Journal</i> , 2012 , 33, 2125-126	3.5	15
476	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Journal of Heart Failure</i> , 2012 , 14, 803-69	3.1	1892
475	Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. <i>Circulation</i> , 2012 , 126, 2317-23	4.8	73
474	Reply to the letter by Dr Erqou regarding Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients. <i>American Heart Journal</i> , 2012 , 163, e37	1.3	
473	The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>American Heart Journal</i> , 2012 , 164, 878-83	1.3	74
472	Assessment of dyspnea in acute decompensated heart failure: insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1441-8	3.8	29
471	Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure) study. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1598-603	3.8	189
470	Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1785-95	3.8	119
469	The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase II Randomised-Controlled Trial. <i>Journal of Cardiac Failure</i> , 2012 , 18, 883	1	4
468	Interleukin-21--a biomarker of importance in predicting myocardial function following acute infarction?. <i>Cytokine</i> , 2012 , 60, 220-5	1.2	9
467	The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. <i>Life Sciences</i> , 2012 , 91, 743-8	1.9	17
466	DO COUNTRIES OR HOSPITALS WITH LONGER STAYS HAVE LOWER READMISSION RATES? FINDINGS FROM THE ASCEND-HF TRIAL. <i>Journal of the American College of Cardiology</i> , 2012 , 59, E1029	3.8	3
465	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. <i>Revista Espanola De Cardiologia</i> , 2012 , 65, 938.e1-938.e59	0.3	27
464	Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. <i>European Heart Journal</i> , 2012 , 33, 1137-41	3.5	54
463	Heart Failure: Management and Prognosis 2012 , 303-318		
462	Microvolt T-wave alternans testing has no role at present in guiding therapy for patients at high risk of ventricular arrhythmias. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 856	3.8	2

461	Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>European Heart Journal</i> , 2012 , 33, 2290-6	3.5	110
460	B-type natriuretic peptide and glycaemia: an emerging cardiometabolic pathway?. <i>Diabetologia</i> , 2012 , 55, 1240-3	2.4	15
459	Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. <i>PLoS Medicine</i> , 2012 , 9, e1001310	3.6	67
458	How small is too small? A systematic review of center volume and outcome after cardiac transplantation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012 , 5, 783-90	1.3	31
457	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Heart Journal</i> , 2012 , 33, 1787-847	3.5	369 ¹
456	Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 804-11	7.4	99
455	Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. <i>Circulation: Heart Failure</i> , 2012 , 5, 571-8	1.7	129
454	Heart failure in 2011: Heart failure therapy--technology to the fore. <i>Nature Reviews Cardiology</i> , 2012 , 9, 73-4	4.9	2
453	Feasibility/eligibility of T-wave alternans testing in patients with heart failure: should we rethink our current modus operandi?: reply. <i>European Journal of Heart Failure</i> , 2012 , 14, 676-677	3.1	
452	Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. <i>European Journal of Heart Failure</i> , 2012 , 14, 681-95	3.1	57
451	Microvolt T-wave alternans testing should be used to guide arrhythmic therapy in heart failure patients: reply. <i>European Journal of Heart Failure</i> , 2012 , 14, 678-678	3.1	
450	Heart failure and socioeconomic status: accumulating evidence of inequality. <i>European Journal of Heart Failure</i> , 2012 , 14, 138-46	3.1	164
449	Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2012 , 14, 341-3	3.1	664
448	Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. <i>BMJ Open</i> , 2012 , 2,	0.9	19
447	Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. <i>European Heart Journal</i> , 2012 , 33, 2782-95	3.5	121
446	When to stop a clinical trial early for benefit: lessons learned and future approaches. <i>Circulation: Heart Failure</i> , 2012 , 5, 294-302	1.7	18
445	Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012 , 13, 387-93	0.7	45
444	Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. <i>Circulation: Heart Failure</i> , 2012 , 5, 217-25	1.7	51

443	Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?. <i>European Heart Journal</i> , 2012 , 33, 1049-57	3.5	17
442	Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 2127-38	3.8	104
441	Calcium handling in the failing heart and SUMO--weighing the evidence. <i>New England Journal of Medicine</i> , 2011 , 365, 1738-9	18	6
440	Eplerenone in patients with systolic heart failure and mild symptoms. <i>New England Journal of Medicine</i> , 2011 , 364, 11-21	18	1890
439	Effect of nesiritide in patients with acute decompensated heart failure. <i>New England Journal of Medicine</i> , 2011 , 365, 32-43	18	930
438	A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. <i>American Heart Journal</i> , 2011 , 161, 210-219.e1	1.3	47
437	Clinical development of pharmacologic agents for acute heart failure syndromes: a proposal for a mechanistic translational phase. <i>American Heart Journal</i> , 2011 , 161, 224-32	1.3	32
436	Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction. <i>American Heart Journal</i> , 2011 , 161, 1156-62	1.3	10
435	Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. <i>American Heart Journal</i> , 2011 , 162, 685-91	1.3	26
434	Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). <i>American Heart Journal</i> , 2011 , 162, 748-755.e3	1.3	54
433	Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. <i>American Heart Journal</i> , 2011 , 162, 938-948.e2	1.3	116
432	Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. <i>American Heart Journal</i> , 2011 , 162, 900-6	1.3	93
431	Plasma TIMP-4 predicts left ventricular remodeling after acute myocardial infarction. <i>Journal of Cardiac Failure</i> , 2011 , 17, 465-71	1	16
430	Clinical Outcomes at 180 days in the ASCEND-HF Trial: Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2011 , 17, 971	1	6
429	Apixaban versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 365, 981-92	18	5856
428	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , 2011 , 32, 1769-818	3.5	2020
427	ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2011 , 32, 2851-905	3.5	1126
426	The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. <i>Lancet, The</i> , 2011 , 378, 676-83	11.5	236

425	Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. <i>American Journal of Kidney Diseases</i> , 2011 , 58, 717-28	2.2	105
424	Evaluation of the functional status questionnaire in heart failure: a sub-study of the second cardiac insufficiency bisoprolol survival study (CIBIS-II). <i>Cardiovascular Drugs and Therapy</i> , 2011 , 25, 77-85	1.1	8
423	Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: a retrospective analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial. <i>Cardiovascular Drugs and Therapy</i> , 2011 , 25, 315-21	1.1	5
422	Trends in incidence and in short term survival following a subarachnoid haemorrhage in Scotland, 1986-2005: a retrospective cohort study. <i>BMC Neurology</i> , 2011 , 11, 38	0.9	15
421	Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. <i>European Journal of Heart Failure</i> , 2011 , 13, 755-64	3.1	15
420	CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. <i>European Journal of Heart Failure</i> , 2011 , 13, 929-36	3.1	57
419	Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. <i>European Journal of Heart Failure</i> , 2011 , 13, 148-53	3.1	56
418	Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. <i>European Journal of Heart Failure</i> , 2011 , 13, 347-57	3.1	430
417	Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbeopetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. <i>Circulation</i> , 2011 , 124, 2903-8	4.8	68
416	Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. <i>Heart</i> , 2011 , 97, 740-7	1.3	214
415	Heart failure: acute ischemic events in HF--should we include sudden death?. <i>Nature Reviews Cardiology</i> , 2011 , 8, 192-3	4.9	
414	The Heart failure and Optimal Outcomes from Pharmacy Study (HOOPS): rationale, design, and baseline characteristics. <i>European Journal of Heart Failure</i> , 2011 , 13, 917-24	3.1	11
413	Self-care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2011 , 13, 115-26	3.1	257
412	Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. <i>European Journal of Heart Failure</i> , 2011 , 13, 107-14	3.1	93
411	Associations of albuminuria in patients with chronic heart failure: findings in the Aliskiren Observation of heart Failure Treatment study. <i>European Journal of Heart Failure</i> , 2011 , 13, 746-54	3.1	25
410	Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction. <i>European Journal of Heart Failure</i> , 2011 , 13, 1305-13	3.1	34
409	Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). <i>Circulation: Heart Failure</i> , 2011 , 4, 27-35	1.7	184
408	Darbeopetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011 , 6, 845-55	1.8	43

407	Circumstances and outcomes of sudden unexpected death in patients with high-risk myocardial infarction: implications for prevention. <i>Circulation</i> , 2011 , 123, 2674-80	4.8	14
406	Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. <i>Circulation: Heart Failure</i> , 2011 , 4, 561-8	1.7	80
405	Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. <i>European Heart Journal</i> , 2011 , 32, 1227-34	3.5	114
404	Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. <i>Circulation: Heart Failure</i> , 2011 , 4, 569-77	1.7	173
403	Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. <i>Circulation</i> , 2011 , 124, 2491-501	4.8	322
402	Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. <i>Diabetes Care</i> , 2011 , 34, 1394-6	3.9	23
401	Neurohormonal activation in acute heart failure: results from VERITAS. <i>Cardiology</i> , 2011 , 119, 96-105	0.4	44
400	Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. <i>Diabetes Care</i> , 2010 , 33, 1213-8	3.9	106
399	Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. <i>Circulation</i> , 2010 , 122, 597-602	4.8	148
398	Erythropoietic response and outcomes in kidney disease and type 2 diabetes. <i>New England Journal of Medicine</i> , 2010 , 363, 1146-55	18	344
397	Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. <i>Circulation</i> , 2010 , 121, 1393-405	4.8	241
396	Estimating the impact of stroke unit care in a whole population: an epidemiological study using routine data. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 1301-5	2.1	34
395	Corrigendum to: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) [Eur	3.5	111
394	The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction. <i>European Journal of Heart Failure</i> , 2010 , 12, 1229-37	3.1	37
393	2010 focused update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. <i>European Journal of</i>	3.1	118
392	Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis. <i>European Journal of Heart Failure</i> , 2010 , 12, 936-42	3.1	29
391	Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Journal of Heart Failure</i> , 2010 , 12, 738-45	3.1	9
390	Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. <i>European Journal of Heart Failure</i> , 2010 , 12, 557-65	3.1	51

389	Microvascular obstruction remains a portent of adverse remodeling in optimally treated patients with left ventricular systolic dysfunction after acute myocardial infarction. <i>Circulation: Cardiovascular Imaging</i> , 2010 , 3, 360-7	1	57
388	Effect of valsartan on the incidence of diabetes and cardiovascular events. <i>New England Journal of Medicine</i> , 2010 , 362, 1477-90	18	493
387	Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction. <i>Heart</i> , 2010 , 96, 533-8	1.3	68
386	Iron deficiency: an ominous sign in patients with systolic chronic heart failure. <i>European Heart Journal</i> , 2010 , 31, 1872-80	3.5	379
385	Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. <i>European Journal of Heart Failure</i> , 2010 , 12, 17-24	3.1	65
384	Corrigendum to ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 [Eur Heart J 2008;29:2388-442 and Eur J Heart Fail 2008;10:933-989]. <i>European Journal of Heart Failure</i> , 2010 , 12, 416-416	3.1	1
383	Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. <i>Heart</i> , 2010 , 96, 838-42	1.3	22
382	An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. <i>European Journal of Heart Failure</i> , 2010 , 12, 66-74	3.1	15
381	Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. <i>European Journal of Heart Failure</i> , 2010 , 12, 607-16	3.1	50
380	Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. <i>European Heart Journal</i> , 2010 , 31, 824-31	3.5	176
379	Evaluating dyspnoea in acute heart failure: progress at last!. <i>European Heart Journal</i> , 2010 , 31, 771-2	3.5	8
378	Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. <i>European Journal of Heart Failure</i> , 2010 , 12, 422-33	3.1	436
377	Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. <i>European Heart Journal</i> , 2010 , 31, 211-21	3.5	38
376	Effect of nateglinide on the incidence of diabetes and cardiovascular events. <i>New England Journal of Medicine</i> , 2010 , 362, 1463-76	18	358
375	Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 243-50	3.8	216
374	Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1196-204	3.8	81
373	Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1812-22	3.8	210
372	Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA). <i>European Journal of Heart Failure</i> , 2010 , 12, 698-705	3.1	20

371	Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2010 , 31, 2369-429	3.5	3452
370	Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. <i>Journal of Cardiac Failure</i> , 2010 , 16, 128-34	1	47
369	Monocyte chemoattractant protein-1: a dichotomous role in cardiac remodeling following acute myocardial infarction in man?. <i>Cytokine</i> , 2010 , 50, 158-62	1.2	17
368	Apixaban for reduction in stroke and other Thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. <i>American Heart Journal</i> , 2010 , 159, 331-9	1.3	345
367	Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). <i>American Heart Journal</i> , 2010 , 160, 145-51	1.3	32
366	Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials. <i>Cardiovascular Therapeutics</i> , 2010 , 28, 124-32	0.8	7
365	2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. <i>Europace</i> , 2010 , 12, 1526-36	1	158
364	Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. <i>Lancet, The</i> , 2010 , 375, 735-42	11.5	1644
363	Rationale and design of the Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF). <i>European Journal of Heart Failure</i> , 2010 , 12, 617-22	3.1	57
362	2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. <i>European Heart Journal</i> , 2010 , 31, 1526-36	3.5	335
361	Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). <i>Europace</i> , 2010 , 12, 1360-420	1	1120
360	Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. <i>Circulation</i> , 2010 , 121, 1465-73	4.8	319
359	Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2010 , 12, 767-78	3.1	569
358	Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. <i>Circulation: Heart Failure</i> , 2010 , 3, 314-25	1.7	120
357	Clinical practice. Systolic heart failure. <i>New England Journal of Medicine</i> , 2010 , 362, 228-38	18	324
356	Biomarkers in heart failure: a clinical review. <i>Heart Failure Reviews</i> , 2010 , 15, 251-73	1.3	19
355	Temporal trends in hospitalisation for stroke recurrence following incident hospitalisation for stroke in Scotland. <i>BMC Medicine</i> , 2010 , 8, 23	2.9	24
354	Age- and sex-specific trends in fatal incidence and hospitalized incidence of stroke in Scotland, 1986 to 2005. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009 , 2, 475-83	1.3	19

353	Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. <i>European Heart Journal</i> , 2009 , 30, 2226-32	3.5	72
352	What works in chronic care management: the case of heart failure. <i>Health Affairs</i> , 2009 , 28, 179-89	2.2	166
351	Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2009 , 11, 119-29	3.1	248
350	Cardiac and extracardiac abnormalities detected by cardiac magnetic resonance in a post-myocardial infarction cohort. <i>Cardiology</i> , 2009 , 113, 1-8	0.4	9
349	Sex differences in incidence, mortality, and survival in individuals with stroke in Scotland, 1986 to 2005. <i>Stroke</i> , 2009 , 40, 1038-43	1.8	60
348	Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial infarcTion trial (VALIANT). <i>European Heart Journal</i> , 2009 , 30, 1450-6	3.5	40
347	Should beta-blockade continue to be withheld from patients with chronic heart failure and asthma?: reply. <i>European Heart Journal</i> , 2009 , 30, 1287-1288	3.5	
346	Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. <i>European Journal of Heart Failure</i> , 2009 , 11, 684-90	3.1	57
345	Corrigendum to ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 [Eur Heart J 2008;29:2388-442 and Eur J Heart Fail 2008;10:933-89]. <i>European Journal of Heart Failure</i> , 2009 , 11, 110-110	3.1	3
344	Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2009 , 11, 433-43	3.1	350
343	The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis. <i>European Journal of Heart Failure</i> , 2009 , 11, 855-62	3.1	99
342	Adherence to medication according to sex and age in the CHARM programme. <i>European Journal of Heart Failure</i> , 2009 , 11, 1092-8	3.1	80
341	Red cell distribution width has incremental prognostic value to B-type natriuretic peptide in acute heart failure. <i>European Journal of Heart Failure</i> , 2009 , 11, 1152-4	3.1	34
340	Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. <i>European Journal of Heart Failure</i> , 2009 , 11, 130-9	3.1	324
339	Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. <i>European Journal of Heart Failure</i> , 2009 , 11, 281-91	3.1	102
338	Design of the Reduction of Events with Darbeoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. <i>European Journal of Heart Failure</i> , 2009 , 11, 795-801	3.1	88
337	Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 1663-71	1.2	245
336	Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. <i>Circulation</i> , 2009 , 119, 515-23	4.8	393

335	Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. <i>Diabetes Care</i> , 2009 , 32, 915-20	3.9	49
334	Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. <i>European Journal of Heart Failure</i> , 2009 , 11, 170-7	3.1	247
333	Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). <i>American Journal of Cardiology</i> , 2009 , 104, 151-7	0.7	13
332	Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2009 , 54, 59-69	2.2	48
331	Pharmacologic management of patients with both heart failure and diabetes. <i>Current Heart Failure Reports</i> , 2009 , 6, 126-32	1	3
330	A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. <i>New England Journal of Medicine</i> , 2009 , 361, 2019-32	18	1695
329	Plasma apelin concentration is depressed following acute myocardial infarction in man. <i>European Journal of Heart Failure</i> , 2009 , 11, 551-8	3.1	61
328	Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). <i>American Heart Journal</i> , 2009 , 157, 271-7	1.3	123
327	Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect?. <i>American Heart Journal</i> , 2009 , 157, 1088-96	1.3	47
326	Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. <i>American Heart Journal</i> , 2009 , 157, 957-70	1.3	43
325	Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. <i>American Heart Journal</i> , 2009 , 158, 896-901.e3	1.3	166
324	Selecting patients for cardiac resynchronization therapy: the fallacy of echocardiographic dyssynchrony. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 1944-59	3.8	60
323	Dual renin-angiotensin system blockade in heart failure. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 278; author reply 279-80	3.8	1
322	Dual renin-angiotensin system blockade and kidney disease. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 278-9; author reply 279-80	3.8	10
321	Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). <i>Journal of the American College of Cardiology</i> , 2009 , 54, 1850-9	3.8	165
320	Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. <i>Lancet, The</i> , 2009 , 373, 2125-35	11.5	1059
319	Albuminuria in chronic heart failure: prevalence and prognostic importance. <i>Lancet, The</i> , 2009 , 374, 543-50	5.5	191
318	Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>European Journal of Heart Failure</i> , 2009 , 11, 292-8	3.1	77

317	Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. <i>Circulation</i> , 2009 , 120, 2188-96	4.8	138
316	Heart failure and chronic obstructive pulmonary disease: lung function test interpretation: reply. <i>European Journal of Heart Failure</i> , 2009 , 11, 632-633	3.1	
315	Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo study. <i>European Heart Journal</i> , 2009 , 30, 56-65	3.5	94
314	Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. <i>European Heart Journal</i> , 2009 , 30, 338-45	3.5	19
313	The complex nature of informal care in home-based heart failure management. <i>Journal of Advanced Nursing</i> , 2008 , 61, 373-83	0.9	80
312	Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus. <i>American Journal of Cardiology</i> , 2008 , 101, 925-9	0.7	19
311	Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 1865-71	3.8	12
310	Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 2000-7	3.8	39
309	Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. <i>JACC: Cardiovascular Imaging</i> , 2008 , 1, 582-91	2	172
308	Irbesartan in patients with heart failure and preserved ejection fraction. <i>New England Journal of Medicine</i> , 2008 , 359, 2456-67	18	1307
307	Prognostic impact of pulmonary arterial hypertension: a population-based analysis. <i>International Journal of Cardiology</i> , 2008 , 124, 183-7	0.8	17
306	Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. <i>American Heart Journal</i> , 2008 , 155, 87-93 ³		24
305	High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. <i>American Heart Journal</i> , 2008 , 155, 706-11	1.3	21
304	Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. <i>American Heart Journal</i> , 2008 , 156, 623-32	1.3	72
303	Determining the most appropriate components for a composite clinical trial outcome. <i>American Heart Journal</i> , 2008 , 156, 633-40	1.3	33
302	Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. <i>Journal of Cardiac Failure</i> , 2008 , 14, 467-74	1	69
301	Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study). <i>American Journal of Cardiology</i> , 2008 , 101, 607-12	0.7	158
300	Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2008 , 371, 1761-8	11.5	149

299	Corrigendum to ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 [Eur Heart J 2008;29:2388-2442 and Eur J Heart Fail 2008;10:933-989] The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). <i>European Heart Journal</i> , 2008, 29, 3069-3074	3.5	10
298	Discordant short- and long-term outcomes associated with diabetes in patients with heart failure: importance of age and sex: a population study of 5.1 million people in Scotland. <i>Circulation: Heart Failure</i> , 2008, 1, 234-41	1.7	51
297	Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. <i>European Heart Journal</i> , 2008, 29, 748-56	3.5	76
296	Diabetes, left ventricular systolic dysfunction, and chronic heart failure. <i>European Heart Journal</i> , 2008, 29, 1224-40	3.5	152
295	Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. <i>European Heart Journal</i> , 2008, 29, 1739-52	3.5	70
294	Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. <i>European Heart Journal</i> , 2008, 29, 3022-8	3.5	25
293	Transthoracic echocardiography: a survey of current practice in the UK. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2008, 101, 345-9	1	14
292	Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. <i>European Journal of Heart Failure</i> , 2008, 10, 149-56	3.1	144
291	Predominance of heart failure in the Heart of Soweto Study cohort: emerging challenges for urban African communities. <i>Circulation</i> , 2008, 118, 2360-7	4.8	128
290	Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Add-on trial. <i>European Journal of Heart Failure</i> , 2008, 10, 157-63	3.1	23
289	A randomised trial of a pre-synaptic stimulator of DA2-dopaminergic and alpha2-adrenergic receptors on morbidity and mortality in patients with heart failure. <i>European Journal of Heart Failure</i> , 2008, 10, 89-95	3.1	30
288	The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. <i>Archives of Internal Medicine</i> , 2008, 168, 1400-704		165
287	Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. <i>Hypertension</i> , 2008, 51, 48-54	2.4	53
286	Heart failure after acute myocardial infarction: a lost battle in the war on heart failure?. <i>Circulation</i> , 2008, 118, 2019-21	4.8	81
285	Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. <i>Circulation: Heart Failure</i> , 2008, 1, 17-24	1.7	292
284	Increased mortality after dronedarone therapy for severe heart failure. <i>New England Journal of Medicine</i> , 2008, 358, 2678-87	18	708
283	Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , 2008, 29, 2641-50	3.5	135
282	How should we optimize cardiac resynchronization therapy?. <i>European Heart Journal</i> , 2008, 29, 2458-72	3.5	50

281	Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , 2008 , 29, 1377-85	3.5	419
280	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). <i>European Journal of Heart Failure</i> 2008, 10, 933-80	3.1	1355
279	Medical management of advanced heart failure. <i>Progress in Palliative Care</i> , 2008 , 16, 229-240	0.5	
278	Approaches to the treatment of anaemia in patients with chronic heart failure. <i>Heart Failure Reviews</i> , 2008 , 13, 431-8	1.3	12
277	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). <i>European Heart Journal</i> , 2008 , 29, 2551-84	3.5	2298
276	Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience. <i>Heart Rhythm</i> , 2007 , 4, 308-13	1.3	17
275	A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 1696-704	3.8	170
274	The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the VALIANT Echo Study. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 1238-45	3.8	64
273	Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 1959-66	3.8	129
272	Corrigendum to Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker [European Journal of Heart Failure 9/4 (2007) 429-434]. <i>European Journal of Heart Failure</i> , 2007 , 9, 1074-1074	3.1	
271	Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY. <i>Cardiovascular Drugs and Therapy</i> , 2007 , 21, 459-65	1.1	21
270	Rosuvastatin in older patients with systolic heart failure. <i>New England Journal of Medicine</i> , 2007 , 357, 2248-61	18	1098
269	Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2007 , 9, 684-94	3.1	265
268	Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. <i>European Journal of Heart Failure</i> , 2007 , 9, 1120-7	3.1	59
267	Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>Circulation</i> , 2007 , 116, 627-36	4.8	264
266	Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. <i>European Journal of Heart Failure</i> , 2007 , 9, 83-91	3.1	138
265	Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker. <i>European Journal of Heart Failure</i> , 2007 , 9, 429-34	3.1	47
264	Differences in arterial compliance, microvascular function and venous capacitance between patients with heart failure and either preserved or reduced left ventricular systolic function. <i>European Journal of Heart Failure</i> , 2007 , 9, 865-71	3.1	53

263	Is microvolt T-wave alternans the answer to risk stratification in heart failure?. <i>Circulation</i> , 2007 , 116, 2984-91	4.8	20
262	Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function. <i>European Heart Journal</i> , 2007 , 28, 326-33	3.5	72
261	Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. <i>European Heart Journal</i> , 2007 , 28, 829-35	3.5	139
260	Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. <i>New England Journal of Medicine</i> , 2007 , 357, 28-38	18	618
259	Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 298, 2009-19	7.4	289
258	A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. <i>Heart</i> , 2007 , 93, 606-12	1.3	119
257	Dysglycemia and heart failure hospitalization: what is the link?. <i>Circulation</i> , 2007 , 115, 1334-5	4.8	8
256	Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. <i>European Journal of Heart Failure</i> , 2007 , 9, 510-7	3.1	38
255	An epidemiological study of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2007 , 30, 104-9	2.9	540
254	Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>Circulation</i> , 2007 , 115, 3111-20	4.8	188
253	Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. <i>Circulation</i> , 2007 , 116, 1482-7	4.8	400
252	Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT Trial. <i>European Heart Journal</i> , 2007 , 28, 685-91	3.5	43
251	Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 40-7	3.8	630
250	Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. <i>European Heart Journal</i> , 2007 , 28, 230-68	3.5	1105
249	Epidemiology of heart failure and left ventricular dysfunction after acute myocardial infarction. <i>Current Heart Failure Reports</i> , 2006 , 3, 175-80	1	39
248	Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance. <i>American Journal of Cardiology</i> , 2006 , 97, 13F-25F	0.7	159
247	¿Cuándo deberé ser el fármaco que se añadiera a un IECA y un bloqueador beta en la insuficiencia cardiaca por disfunción sistólica: un antagonista de la aldosterona o un ARA-II? Evidencias clínicas con ambos. <i>Revista Espanola De Cardiologia Suplementos</i> , 2006 , 6, 29C-36C	0	
246	Beta-blockers and heart failure in older people: reply. <i>European Heart Journal</i> , 2006 , 27, 888-889	3.5	2

245	Selecting patients for cardiac resynchronization therapy: electrical or mechanical dyssynchrony?. <i>European Heart Journal</i> , 2006 , 27, 1270-81	3.5	138
244	Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. <i>European Heart Journal</i> , 2006 , 27, 2257-9	3.5	17
243	QRS duration alone to select patients for cardiac resynchronization therapy: flying in the face of the evidence?. <i>European Heart Journal</i> , 2006 , 27, 3074-5; author reply 3075	3.5	4
242	Treatment of chronic heart failure: a comparison between the major guidelines. <i>European Heart Journal</i> , 2006 , 27, 1773-7	3.5	40
241	Effect of socioeconomic deprivation on the population risk of incident heart failure hospitalisation: an analysis of the Renfrew/Paisley Study. <i>European Journal of Heart Failure</i> , 2006 , 8, 856-63	3.1	32
240	Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2006 , 8, 591-8	3.1	92
239	Anaemia is an independent predictor of mortality in patients with left ventricular systolic dysfunction following acute myocardial infarction. <i>European Journal of Heart Failure</i> , 2006 , 8, 577-84	3.1	26
238	Does aspirin reduce the benefit of an angiotensin-converting enzyme inhibitor? Choosing between the Scylla of observational studies and the Charybdis of subgroup analysis. <i>Circulation</i> , 2006 , 113, 2566-8	4.8	6
237	Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. <i>Circulation</i> , 2006 , 113, 671-8	4.8	694
236	Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. <i>Circulation</i> , 2006 , 113, 986-94	4.8	194
235	Predictors of mortality and morbidity in patients with chronic heart failure. <i>European Heart Journal</i> , 2006 , 27, 65-75	3.5	680
234	Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. <i>Circulation</i> , 2006 , 114, 1028-35	4.8	241
233	Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , 2006 , 27, 1447-58	3.5	29
232	Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. <i>Heart Rhythm</i> , 2006 , 3, 313-6	1.3	45
231	The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>Journal of the American College of Cardiology</i> , 2006 , 47, 726-33	3.8	120
230	Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 1997-2004	3.8	406
229	Using measures of disease progression to determine therapeutic effect: a sirens' song. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 434-7	3.8	18
228	Chilling findings: the need for winter vigilance in heart failure. <i>Journal of Cardiac Failure</i> , 2006 , 12, 120-11		1

227	The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry. <i>American Heart Journal</i> , 2006 , 151, 206-12	1.3	58
226	Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. <i>American Heart Journal</i> , 2006 , 151, 985-91	1.3	218
225	The prevalence, nature, and importance of hematologic abnormalities in heart failure. <i>American Heart Journal</i> , 2006 , 151, 1313-21	1.3	46
224	Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. <i>American Heart Journal</i> , 2006 , 152, 183-9	1.3	17
223	Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. <i>American Heart Journal</i> , 2006 , 151, 985-91	1.3	90
222	Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. <i>American Heart Journal</i> , 2006 , 152, 500-8	1.3	7
221	Patients strategies for managing medication for chronic heart failure. <i>International Journal of Cardiology</i> , 2006 , 109, 66-73	0.8	30
220	Mapping the emergence of heart disease in a black, urban population in Africa: the Heart of Soweto Study. <i>International Journal of Cardiology</i> , 2006 , 108, 101-8	0.8	40
219	Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15 000 middle-aged men and women (the Renfrew-Paisley study). <i>European Heart Journal</i> , 2006 , 27, 96-106	3.5	220
218	Aldosterone blockade in post-acute myocardial infarction heart failure. <i>Clinical Cardiology</i> , 2006 , 29, 434-8	0.7	4
217	The treatment of heart failure with preserved ejection fraction ("diastolic heart failure"). <i>Heart Failure Reviews</i> , 2006 , 11, 141-6	1.3	25
216	Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>American Heart Journal</i> , 2006 , 152, 86-92	1.3	51
215	Angiotensin receptor blockers and myocardial infarction: analysis of evidence is incomplete and inaccurate. <i>BMJ, The</i> , 2005 , 330, 1269; author reply 1270-1	2.2	6
214	Making sense of SENIORS. <i>European Heart Journal</i> , 2005 , 26, 203-6	3.5	23
213	Low pulse pressure is independently related to elevated natriuretic peptides and increased mortality in advanced chronic heart failure. <i>European Heart Journal</i> , 2005 , 26, 1759-64	3.5	62
212	Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. <i>European Heart Journal</i> , 2005 , 26, 2114-9	3.5	24
211	Public awareness of heart failure in Europe: first results from SHAPE. <i>European Heart Journal</i> , 2005 , 26, 2413-21	3.5	85
210	The role of angiotensin II receptor blockers in the management of heart failure. <i>Country Review Ukraine</i> , 2005 , 7, J10-J14		1

209	Heart failure. <i>Lancet, The</i> , 2005 , 365, 1877-89	11.5	626
208	Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. <i>Lancet, The</i> , 2005 , 366, 2005-11	11.5	327
207	A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. <i>European Journal of Heart Failure</i> , 2005 , 7, 1059-69	3.1	113
206	Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United Kingdom. <i>International Journal of Cardiology</i> , 2005 , 100, 143-9 ^{0.8}	0.8	11
205	Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>American Heart Journal</i> , 2005 , 150, 323-9	1.3	22
204	Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. <i>American Heart Journal</i> , 2005 , 149, 408-13	1.3	97
203	Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). <i>American Heart Journal</i> , 2005 , 150, 46-53	1.3	58
202	Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. <i>Journal of Cardiac Failure</i> , 2005 , 11, 12-20	1	205
201	The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. <i>Journal of Cardiac Failure</i> , 2005 , 11, 576-85	1	113
200	Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 525-30	3.8	201
199	Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. <i>New England Journal of Medicine</i> , 2005 , 352, 1071-80	18	1675
198	Review: Optimising the use of Angiotensin Receptor Blockers in the Management of Chronic Heart Failure. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2005 , 6, S2-S5	0.7	
197	Heart failure management programs reduce readmissions and prolong survival. <i>Archives of Internal Medicine</i> , 2005 , 165, 1311; author reply 1311-2		8
196	Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation. <i>Country Review Ukraine</i> , 2005 , 7, C41-C54		7
195	Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 294, 1794-8	7.4	54
194	Chronic kidney disease in patients with cardiac disease: a review of evidence-based treatment. <i>Kidney International</i> , 2005 , 68, 1419-26	2.7	9
193	Neurohumoral pathways in heart failure with preserved systolic function. <i>Progress in Cardiovascular Diseases</i> , 2005 , 47, 357-66	1.9	58
192	Aspirin inhibits the acute arterial and venous vasodilator response to captopril in patients with chronic heart failure. <i>Cardiovascular Drugs and Therapy</i> , 2005 , 19, 261-5	1.1	11

191	Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke. An imputed placebo analysis. <i>Cardiovascular Drugs and Therapy</i> , 2005 , 19, 149-51	1.1	2
190	A qualitative study of the contribution of pharmacists to heart failure management in Scotland. <i>International Journal of Clinical Pharmacy</i> , 2005 , 27, 453-8		16
189	EXPERT CONSENSUS DOCUMENT ON ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE. <i>Rational Pharmacotherapy in Cardiology</i> , 2005 , 1, 49-69	0.2	0
188	How much responsibility should heart failure nurses take?. <i>European Journal of Heart Failure</i> , 2005 , 7, 351-61	3.1	33
187	Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. <i>European Journal of Heart Failure</i> , 2005 , 7, 650-6	3.1	20
186	Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. <i>Circulation</i> , 2005 , 112, 3738-44	4.8	540
185	Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. <i>Circulation</i> , 2005 , 112, 48-53	4.8	185
184	Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. <i>Circulation</i> , 2005 , 111, 3411-9	4.8	207
183	Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>Circulation</i> , 2005 , 112, 3391-9	4.8	93
182	Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. <i>New England Journal of Medicine</i> , 2005 , 352, 2581-8	18	588
181	Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. <i>European Journal of Heart Failure</i> , 2005 , 7, 710-21	3.1	94
180	Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005 , 2, 128-9		4
179	Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , 2004 , 25, 1920-6	3.5	37
178	Treatment of heart failure with spironolactone--trial and tribulations. <i>New England Journal of Medicine</i> , 2004 , 351, 526-8	18	57
177	Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. <i>European Heart Journal</i> , 2004 , 25, 1454-70	3.5	176
176	A putative placebo comparison of the SCOPE and LIFE trials. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2004 , 5, 59-63	0.7	6
175	Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>Circulation</i> , 2004 , 110, 2180-3	4.8	203
174	Expert consensus document on beta-adrenergic receptor blockers. <i>European Heart Journal</i> , 2004 , 25, 1341-62	3.5	365

173	Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?. <i>Circulation</i> , 2004 , 110, 3281-8	4.8	58
172	Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. <i>Circulation</i> , 2004 , 110, 1572-8	4.8	167
171	Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). <i>Circulation</i> , 2004 , 109, 1594-602	4.8	856
170	Anemia and its relationship to clinical outcome in heart failure. <i>Circulation</i> , 2004 , 110, 149-54	4.8	314
169	Angiotensin inhibition in heart failure. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2004 , 5 Suppl 1, S17-22	0.7	12
168	Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. <i>Circulation</i> , 2004 , 110, 2618-26	4.8	282
167	The clinical relevance of adrenomedullin: a promising profile? 2004 , 103, 179-201		87
166	17ss oestradiol does not attenuate the response to angiotensin I and II during long term therapy in postmenopausal women. <i>Cardiovascular Drugs and Therapy</i> , 2004 , 18, 31-6	1.1	2
165	Increasing awareness and perception of heart failure in Europe and improving care--rationale and design of the SHAPE Study. <i>Cardiovascular Drugs and Therapy</i> , 2004 , 18, 153-9	1.1	13
164	Anemia and heart failure. <i>Current Heart Failure Reports</i> , 2004 , 1, 176-82	1	26
163	An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. <i>European Heart Journal</i> , 2004 , 25, 1911-9	3.5	98
162	Documento de Consenso de Expertos sobre el uso de inhibidores de la enzima de conversi3n de la angiotensina en la enfermedad cardiovascular. <i>Revista Espanola De Cardiologia</i> , 2004 , 57, 1213-1232	0.3	1
161	Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 317-27	3.8	615
160	The year in heart failure. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 2398-405	3.8	9
159	Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. <i>Journal of Cardiac Failure</i> , 2004 , 10, 155-64	1	55
158	What are the clinical consequences of anemia in patients with chronic heart failure?. <i>Journal of Cardiac Failure</i> , 2004 , 10, S10-2	1	15
157	Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. <i>New England Journal of Medicine</i> , 2004 , 351, 1285-95	18	1464
156	Digitalis for treatment of congestive heart failure in patients in sinus rhythm. <i>Cochrane Database of Systematic Reviews</i> , 2004 , CD002901		15

155	Seasonal variation in morbidity and mortality related to atrial fibrillation. <i>International Journal of Cardiology</i> , 2004 , 97, 283-8	0.8	27
154	Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2004 , 364, 347-54	11.5	275
153	Clinical assessment and investigation of patients with suspected heart failure 2004 , 75-91		
152	VALsartan In Acute myocardial INfarcTion (VALIANT) trial: baseline characteristics in context. <i>European Journal of Heart Failure</i> , 2003 , 5, 537-44	3.1	58
151	Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Journal of Heart Failure</i> , 2003 , 5, 261-70	3.1	98
150	Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. <i>New England Journal of Medicine</i> , 2003 , 349, 1893-906	18	1892
149	Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. <i>Lancet, The</i> , 2003 , 362, 759-66	11.5	1506
148	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. <i>Lancet, The</i> , 2003 , 362, 767-71	11.5	1502
147	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. <i>Lancet, The</i> , 2003 , 362, 772-6	11.5	1362
146	Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. <i>Lancet, The</i> , 2003 , 362, 777-81	11.5	2087
145	The CHARM programme. <i>Lancet, The</i> , 2003 , 362, 1678-1679	11.5	3
144	The statin wars. <i>Lancet, The</i> , 2003 , 362, 1854; discussion 1856	11.5	6
143	Angiotensin receptor blockers in heart failure. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2003 , 4, 171-5	0.7	4
142	Effect of aspirin on vasodilation to bradykinin and substance P in patients with heart failure treated with ACE inhibitor. <i>British Journal of Clinical Pharmacology</i> , 2002 , 53, 37-42	0.9	6
141	Myocardial infarct: no one size fits all. <i>Circulation</i> , 2002 , 105, 2577-9	4.8	3
140	Substantial between-hospital variation in outcome following first emergency admission for heart failure. <i>European Heart Journal</i> , 2002 , 23, 650-7	3.5	19
139	New therapeutic options in congestive heart failure: Part II. <i>Circulation</i> , 2002 , 105, 2223-8	4.8	69
138	New therapeutic options in congestive heart failure: Part I. <i>Circulation</i> , 2002 , 105, 2099-106	4.8	99

137	Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart?. <i>Circulation</i> , 2002 , 106, 292-5	4.8	78
136	Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). <i>Circulation</i> , 2002 , 106, 920-6	4.8	493
135	The current cost of heart failure to the National Health Service in the UK. <i>European Journal of Heart Failure</i> , 2002 , 4, 361-71	3.1	378
134	An economic analysis of specialist heart failure nurse management in the UK; can we afford not to implement it?. <i>European Heart Journal</i> , 2002 , 23, 1369-78	3.5	59
133	Palliative care for heart failure. <i>BMJ, The</i> , 2002 , 325, 915-6	2.2	57
132	A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. <i>American Journal of Medicine</i> , 2002 , 113, 359-64	0.6	1087
131	Heart failure in a cold climate. Seasonal variation in heart failure-related morbidity and mortality. <i>Journal of the American College of Cardiology</i> , 2002 , 39, 760-6	3.8	152
130	Statins and chronic heart failure: do we need a large-scale outcome trial?. <i>Journal of the American College of Cardiology</i> , 2002 , 39, 1567-73	3.8	110
129	Trends in case-fatality in 22968 patients admitted for the first time with atrial fibrillation in Scotland, 1986-1995. <i>International Journal of Cardiology</i> , 2002 , 82, 229-36	0.8	31
128	Amlodipine for all undergoing PCI? The evidence is unconvincing. <i>International Journal of Cardiology</i> , 2002 , 84, 30-32	0.8	2
127	Current management of heart failure. <i>Practitioner</i> , 2002 , 246, 438-43		1
126	Effect of adrenomedullin on the production of endothelin-1 and on its vasoconstrictor action in resistance arteries: evidence for a receptor-specific functional interaction in patients with heart failure. <i>Clinical Science</i> , 2001 , 101, 45-51	1.7	7
125	Effect of adrenomedullin on the production of endothelin-1 and on its vasoconstrictor action in resistance arteries: evidence for a receptor-specific functional interaction in patients with heart failure. <i>Clinical Science</i> , 2001 , 101, 45	1.7	8
124	Relation between socioeconomic deprivation and death from a first myocardial infarction in Scotland: population based analysis. <i>BMJ: British Medical Journal</i> , 2001 , 322, 1152-3		47
123	Effect of neutral endopeptidase inhibition on the actions of adrenomedullin and endothelin-1 in resistance arteries from patients with chronic heart failure. <i>Hypertension</i> , 2001 , 38, 412-6	2.4	8
122	Impaired endothelial function in isolated human uremic resistance arteries. <i>Kidney International</i> , 2001 , 60, 1077-82	2.7	100
121	Effects of adrenomedullin on angiotensin II stimulated atrial natriuretic peptide and arginine vasopressin secretion in healthy humans. <i>British Journal of Clinical Pharmacology</i> , 2001 , 52, 165-8	0.9	7
120	Clinical experience with endothelin receptor antagonists in chronic heart failure. <i>Heart Failure Reviews</i> , 2001 , 6, 317-23	1.3	17

119	Are angiotensin II receptor blockers more efficacious than placebo in heart failure? Implications of ELITE-2. Evaluation of Losartan In The Elderly. <i>American Journal of Cardiology</i> , 2001 , 87, 606-7, A9	0.7	13
118	Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II). <i>European Heart Journal</i> , 2001 , 22, 1021-31	3.5	28
117	Signalling mechanisms underlying the myogenic response in human subcutaneous resistance arteries. <i>Cardiovascular Research</i> , 2001 , 49, 828-37	2.5	27
116	Trends in hospitalization for heart failure in Scotland, 1990-1996. An epidemic that has reached its peak?. <i>European Heart Journal</i> , 2001 , 22, 209-17	3.5	151
115	Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986--1996. <i>European Heart Journal</i> , 2001 , 22, 693-701	3.5	108
114	Failing ageing hearts. <i>European Heart Journal</i> , 2001 , 22, 1978-90	3.5	24
113	Economics of chronic heart failure. <i>European Journal of Heart Failure</i> , 2001 , 3, 283-91	3.1	254
112	Endothelium-derived hyperpolarizing factor : identification and mechanisms of action in human subcutaneous resistance arteries. <i>Circulation</i> , 2001 , 103, 1702-8	4.8	101
111	Effects of urotensin II in human arteries and veins of varying caliber. <i>Circulation</i> , 2001 , 103, 1378-81	4.8	83
110	Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans. <i>Circulation</i> , 2001 , 104, 1805-8	4.8	40
109	Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 1056-61	3.8	112
108	Attenuation of endothelin-1 induced vasoconstriction by 17beta estradiol is not sustained during long-term therapy in postmenopausal women with coronary heart disease. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 1367-73	3.8	19
107	Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 1234-8	3.8	22
106	Gender and survival: a population-based study of 201,114 men and women following a first acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2001 , 38, 729-35	3.8	112
105	Endothelin receptor antagonists and cardiovascular diseases of aging. <i>Drugs and Aging</i> , 2001 , 18, 425-40	0.8	6
104	ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. <i>American Heart Journal</i> , 2001 , 141, 800-7	1.3	34
103	Electrical cardioversion for atrial fibrillation: outcomes in "real-life" clinical practice. <i>International Journal of Cardiology</i> , 2001 , 81, 29-35	0.8	39
102	Changes in notions about heart failure. <i>Lancet, The</i> , 2001 , 358, 432-4	11.5	46

101	Age, sex, and social trends in out-of-hospital cardiac deaths in Scotland 1986-95: a retrospective cohort study. <i>Lancet, The</i> , 2001 , 358, 1213-7	11.5	88
100	Older and more complicated heart failure patients: an increasing challenge to the health care system!. <i>Coronary Health Care</i> , 2001 , 5, 121-125		1
99	Randomised controlled trial of specialist nurse intervention in heart failure. <i>BMJ: British Medical Journal</i> , 2001 , 323, 715-8		382
98	EARTH: EndothelinA Receptor Antagonist Trial in Heart Failure. <i>Cardiology</i> , 2001 , 1, 294-298		3
97	Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2001 , 2, 89-92	0.7	3
96	Altered diaphragm position and function in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2001 , 3, 183-7	3.1	15
95	Poles apart, but are they the same? A comparative study of Australian and Scottish patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2001 , 3, 249-55	3.1	12
94	Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. <i>European Journal of Heart Failure</i> , 2001 , 3, 495-502	3.1	41
93	More 'malignant' than cancer? Five-year survival following a first admission for heart failure. <i>European Journal of Heart Failure</i> , 2001 , 3, 315-22	3.1	685
92	Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction. <i>Heart</i> , 2001 , 86, 97-103	1.3	
91	Venous endothelin receptor function in patients with chronic heart failure. <i>Clinical Science</i> , 2000 , 98, 65-70	1.7	14
90	Acute heart failure: a practical guide to management. <i>British Journal of Hospital Medicine</i> , 2000 , 61, 725-9		2
89	"I don't like Mondays"-day of the week of coronary heart disease deaths in Scotland: study of routinely collected data. <i>BMJ: British Medical Journal</i> , 2000 , 320, 218-9		46
88	Adrenomedullin selectively inhibits angiotensin II-induced aldosterone secretion in humans. <i>Journal of Hypertension</i> , 2000 , 18, 61-4	0.5	27
87	Heart failure: we need more trials in typical patients. <i>European Heart Journal</i> , 2000 , 21, 699-700	3.5	29
86	Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. <i>Kidney International</i> , 2000 , 57, 1100-6	2.7	116
85	The acute vascular effects of frusemide in heart failure. <i>British Journal of Clinical Pharmacology</i> , 2000 , 50, 9-13	0.9	25
84	Even low-dose aspirin inhibits arachidonic acid-induced vasodilation in heart failure. <i>Clinical Pharmacology and Therapeutics</i> , 2000 , 67, 530-7	1.5	36

83	Why we need new strategies in CHF management. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2000 , 1 Suppl 1, 12-6	0.7	0
82	Impaired endothelium-dependent vasodilatation in uraemia. <i>Nephrology Dialysis Transplantation</i> , 2000 , 15, 1194-200	1.2	86
81	Beta-blockers, ventricular arrhythmias, and sudden death in heart failure: not as simple as it seems. <i>European Heart Journal</i> , 2000 , 21, 1214-5	3.5	3
80	Endothelin receptor antagonism in patients with chronic heart failure. <i>Cardiovascular Research</i> , 2000 , 47, 166-72	2.5	33
79	Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. <i>Circulation</i> , 2000 , 101, 2206-12	4.8	266
78	Explanation for the decline in coronary heart disease mortality rates in Auckland, New Zealand, between 1982 and 1993. <i>Circulation</i> , 2000 , 102, 1511-6	4.8	157
77	Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. <i>American Heart Journal</i> , 2000 , 139, 609-17	1.3	97
76	Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. <i>American Journal of Medicine</i> , 2000 , 109, 489-92	0.6	23
75	Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. <i>American Heart Journal</i> , 2000 , 140, 727-50	1.3	142
74	Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM) Study Programme. <i>Blood Pressure</i> , 2000 , 9, 60	0.4	
73	A comparison of the reproducibility and the sensitivity to change of visual analogue scales, Borg scales, and Likert scales in normal subjects during submaximal exercise. <i>Chest</i> , 1999 , 116, 1208-17	1.2	359
72	Cardiac cachexia--lean and mean. <i>European Heart Journal</i> , 1999 , 20, 1609-11	3.5	5
71	Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure. <i>Circulation</i> , 1999 , 100, 268-73	4.8	41
70	Failure of women's hearts. <i>Circulation</i> , 1999 , 99, 2334-41	4.8	119
69	Effects of resistive breathing on exercise capacity and diaphragm function in patients with ischaemic heart disease. <i>European Journal of Heart Failure</i> , 1999 , 1, 297-300	3.1	12
68	The Lys198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people. <i>Hypertension</i> , 1999 , 33, 1169-74	2.4	164
67	Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. <i>European Heart Journal</i> , 1999 , 20, 1182-90	3.5	84
66	Effect of angiotensin-(1-7) and bradykinin in patients with heart failure treated with an ACE inhibitor. <i>Hypertension</i> , 1999 , 34, 457-60	2.4	58

65	Final consensus statement of the Royal College of Physicians of Edinburgh Consensus Conference on atrial fibrillation in hospital and general practice, 3-4 September 1998. <i>British Journal of Haematology</i> , 1999 , 104, 195-6	1.1	9
64	Elevated serum and monocyte tumour necrosis factor alpha in patients with congestive heart failure. <i>International Journal of Cardiology</i> , 1999 , 71, 263-4	0.8	3
63	Endothelin B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction. <i>Journal of the American College of Cardiology</i> , 1999 , 33, 932-8	3.8	45
62	Impaired vascular responsiveness to nitric oxide in renal transplant recipients. <i>Transplantation Proceedings</i> , 1999 , 31, 304-5	0.3	1
61	Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. <i>Journal of Cardiac Failure</i> , 1999 , 5, 276-82	1	224
60	Prescribing and emergency admissions for heart failure in greater Glasgow. <i>Journal of Cardiac Failure</i> , 1999 , 5, 3-7	1	
59	A review of quality-of-life evaluations in patients with congestive heart failure. <i>Pharmacoeconomics</i> , 1999 , 16, 247-71	1.1	85
58	Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 1999 , 1, 67-72	3.1	33
57	Increasing the impact of cardiological treatments. How best to reduce deaths. <i>European Heart Journal</i> , 1999 , 20, 1386-92	3.5	23
56	The reproducibility of symptoms during a submaximal exercise test in chronic heart failure. <i>British Journal of Clinical Pharmacology</i> , 1998 , 45, 287-90	0.9	6
55	Short-term haemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure. <i>Lancet, The</i> , 1998 , 352, 201-2	11.5	77
54	Biochemical detection of left-ventricular systolic dysfunction. <i>Lancet, The</i> , 1998 , 351, 9-13	11.5	853
53	Endothelin-1 has haemodynamic effects at pathophysiological concentrations in patients with left ventricular dysfunction. <i>Cardiovascular Research</i> , 1998 , 39, 563-70	2.5	18
52	Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. The NETWORK Investigators. <i>European Heart Journal</i> , 1998 , 19, 481-9	3.5	125
51	Importance of heart failure as a cause of death. Changing contribution to overall mortality and coronary heart disease mortality in Scotland 1979-1992. <i>European Heart Journal</i> , 1998 , 19, 1829-35	3.5	70
50	An economic analysis of the Survival and Ventricular Enlargement (SAVE) Study. Application to the United Kingdom. <i>Pharmacoeconomics</i> , 1997 , 12, 182-92	1.1	18
49	Calcium-antagonist controversy: the long and short of it?. <i>Lancet, The</i> , 1997 , 349, 585-6	11.5	11
48	Digoxin for patients with heart failure in sinus rhythm. <i>Lancet, The</i> , 1997 , 350, 519	11.5	

47	Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. <i>Lancet, The</i> , 1997 , 350, 829-33	11.5	492
46	A1 H spin echo and 51V NMR study of the interaction of vanadate with intact erythrocytes. <i>Journal of Biological Inorganic Chemistry</i> , 1997 , 2, 235-241	1	30
45	Analysis of reproducibility of reference lumen quantitation with intravascular ultrasound in stented coronary arteries. <i>Catheterization and Cardiovascular Diagnosis</i> , 1997 , 40, 1-7		11
44	The pharmacoeconomics of ACE inhibitors in chronic heart failure. <i>Pharmacoeconomics</i> , 1996 , 9, 188-97	1.1	34
43	Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. <i>Circulation</i> , 1996 , 94, 2131-7	4.8	119
42	Captopril and norepinephrine-induced hypertrophy and haemodynamics in rats. <i>Journal of Cardiovascular Pharmacology</i> , 1996 , 27, 667-72	0.8	8
41	Concise Guide to the Management of Heart Failure - World Health Organization/Council on Geriatric Cardiology Task Force on Heart Failure Education. <i>The American Journal of Geriatric Cardiology</i> , 1996 , 5, 13-30		4
40	Effects of chronic norepinephrine administration on cardiac function in rats. <i>Journal of Cardiovascular Pharmacology</i> , 1995 , 26, 584-9	0.8	29
39	ACE inhibitors and health-care economics. <i>Coronary Artery Disease</i> , 1995 , 6, 315-9	0.3	6
38	Clinical Trials Report: Cardiovascular & Renal: Ongoing and planned clinical trials in chronic heart failure and left ventricular dysfunction. <i>Expert Opinion on Investigational Drugs</i> , 1995 , 4, 1069-1080	1.8	4
37	The assessment of the HO. scavenging action of therapeutic agents. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1994 , 12, 863-6	1.2	20
36	Alteration of the erythrocyte glutathione redox balance by N-acetylcysteine, captopril and exogenous glutathione. <i>FEBS Letters</i> , 1994 , 347, 215-20	1.1	13
35	Acute effects of captopril on the renal actions of furosemide in patients with chronic heart failure. <i>American Heart Journal</i> , 1993 , 126, 879-86	1.3	24
34	ACE Inhibitors after myocardial Infarction. <i>Lancet, The</i> , 1993 , 342, 1418-1419	11.5	3
33	Effects of a xanthine oxidase/hypoxanthine free radical and reactive oxygen species generating system on endothelial function in New Zealand white rabbit aortic rings. <i>Journal of Cardiovascular Pharmacology</i> , 1993 , 22, 792-7	0.8	43
32	Effects of the xanthine oxidase system on cardiac function in anaesthetised rats. <i>Free Radical Biology and Medicine</i> , 1993 , 15, 249-55	2.1	2
31	Circulating endothelin is not extracted by the pulmonary circulation in man. <i>Chest</i> , 1992 , 102, 1143-4	1.2	14
30	The J-curve hypothesis. <i>Lancet, The</i> , 1992 , 339, 561-2	11.5	1

29	ACE inhibitors for myocardial infarction and unstable angina. <i>Lancet, The</i> , 1992 , 340, 1547-8	11.5	1
28	Comparison of the effects of ANF 99-126 and ANF 103-126 on captopril-induced renin release in man. <i>Clinical Endocrinology</i> , 1991 , 34, 493-9	0.9	
27	Unique cardioprotective potential of angiotensin converting enzyme inhibitors: a hypothesis still to be tested on humans. <i>Journal of Hypertension</i> , 1991 , 9, 393-7	0.5	5
26	Synergism of histidyl dipeptides as antioxidants. <i>Journal of Molecular and Cellular Cardiology</i> , 1991 , 23, 1205-7	1.5	15
25	Effects of xamoterol in acute myocardial infarction: blood pressure, heart rate, arrhythmias and early clinical course. <i>International Journal of Cardiology</i> , 1991 , 31, 295-303	0.8	1
24	Free radical scavenging: a potentially beneficial action of thiol-containing angiotensin converting enzyme inhibitors. <i>Biochemical Society Transactions</i> , 1990 , 18, 1184-5	1.3	33
23	Evidence for enhanced free radical activity in chronic congestive heart failure secondary to coronary artery disease. <i>American Journal of Cardiology</i> , 1990 , 65, 1261-2	0.7	123
22	Neuroendocrine changes post myocardial infarction: effects of xamoterol. <i>American Heart Journal</i> , 1990 , 120, 56-62	1.3	15
21	The Place of Angiotensin-Converting Enzyme Inhibitors in Internal Medicine. <i>Medical Principles and Practice</i> , 1989 , 1, 65-70	1	1
20	Atrial natriuretic factor attenuates prostaglandin E2-stimulated plasma renin activity in humans. <i>Journal of Cardiovascular Pharmacology</i> , 1989 , 14, 326-30	0.8	2
19	Furosemide pretreatment blunts the inhibition of renal tubular sodium reabsorption by ANF in man. <i>European Journal of Clinical Pharmacology</i> , 1988 , 35, 333-8	0.7	3
18	Atrial natriuretic factor inhibits ACTH stimulated aldosterone, but not cortisol, secretion in man. <i>European Journal of Clinical Pharmacology</i> , 1988 , 35, 409-12	0.7	14
17	The place of ACE inhibitors in the current treatment of chronic heart failure. <i>Postgraduate Medical Journal</i> , 1988 , 64, 653-5	1	1
16	The effect of atrial natriuretic factor on urinary albumin and ??; 2-microglobulin excretion in man. <i>Journal of Hypertension</i> , 1988 , 6, 783???786	0.5	10
15	Consequences of fluid loss in patients treated with ACE inhibitors. <i>Postgraduate Medical Journal</i> , 1987 , 63, 385-7	1	11
14	Effect of diarrhoea on a patient taking captopril. <i>Lancet, The</i> , 1985 , 1, 581	11.5	13
13	Coronary Heart Disease and Diabetes37-67		
12	Pathogenesis of Atherosclerosis and Vascular Disease in Type 2 Diabetes16-36		1

- 11 Diabetes and Acute Coronary Syndromes69-92
- 10 Study Acronyms280-286
- 9 Diabetes, Left Ventricular Systolic Dysfunction and Chronic Heart Failure93-134
- 8 Prevention of Diabetes as a Means of Preventing Cardiovascular Disease240-257 1
- 7 Diabetes and Stroke / Transient Ischaemic Attacks175-198
- 6 Diabetes for Cardiologists258-279
- 5 Prevention of Cardiovascular Events in Diabetic Patients223-239
- 4 Diabetes and Peripheral Arterial Disease199-222
- 3 Diabetes and Hypertension135-174
- 2 Excess deaths during the Covid-19 pandemic: An international comparison 17
- 1 Epidemiology of Vascular Disease in Diabetes1-15